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PART A. TREATMENT OF LEAD POISONING 
WITH ORAL PF.NTOTT.TAMTNF.
Section A.I INTRODUCTION
1. History of lead poisoning
The discovery of lead was not recorded but it is mentioned in 
the Old Testament and was known to the Assyrians and early Egyptians. 
Recorded history credits the Romans with the first extensive use 
of lead, mostly for water pipes, and thus to the beginning of its 
history as an occupational disease. The clinical features of lead 
intoxication have long been recognised. Hippocrates first 
described severe abdominal colic although it was not until 1572 
that the term 1 colicT was coined by Citois and became generally 
used to describe the symptoms of lead poisoning. At this time, an 
extensive epidemic, characterised by severe abdominal colic, occurred 
in France in the province of Poitou. This was later identified as 
lead poisoning, the origin of the poisoning being traced to vintners 
who had Tsweetened1 sour wine by the addition of litharge (lead oxide) 
to the wine so that sugar of lead (lead acetate) was formed. In 
1656, Stockhausen recognised that lead poisoning was an occupational 
disease. More than one hundred years later in 1759* Huxham made 
his classical description of Devonshire colicT, later diagnosed by 
Baker (1772) as being caused by the consumption of cider which had 
been adulterated by storage in lead glazed pottery. Huxham reported
2vomiting and constipation, delirium, languor, limb paralysis and 
epilepsy. In 1814, Orfila carried out experimental investigations 
on lead toxicology, the first investigation of its kind since lead 
poisoning had been recognised as an occupational disease, over 
150 years previously. Later, in 1839* a classical description 
of the symptoms of lead intoxication, ■which differs little from that 
of the present day, was elucidated by Tanqueral des Planches. In 
1840, at St. Thomas *s Hospital, London, Burton noted that patients 
on lead oxide therapy, produced a Tblue line* or Burtonian line on 
the gums, one of the recognised diagnostic signs of lead poisoning 
today.
2. Signs and symptoms of lead poisoning
Lead poisoning (plumbism or saturnism) is almost exclusively 
an occupational disease (although it is a hazard in childhood) 
which is normally chronic in nature. It may resemble many 
disorders, rendering diagnosis difficult and may be initially 
asymptomatic or present as a non-specific illness. The poison 
affects the whole body but especially the nervous system, the 
gastrointestinal tract and the blood-forming tissues. Its 
victims become pallid, digestion is deranged and anorexia and 
painful colic with constipation results. The loss of power
is generally shown first in the fingers, hands and wrists and the 
condition known as Twrist drop1 soon follows, rendering the victim 
useless for work. The palsy will extend to the shoulder and 
shortly after to the legs also. Impairment of renal function can 
occur and the sight can be weakened or even lost. One of the 
early signs of lead poisoning is the pallor of the skin giving rise 
to pale lips and an ashen face. The cause of the pallor is not 
known. It occurs before any marked change in blood and cannot be 
explained on the basis of anaemia (Goodman and Gillman, 1955). In 
patients having their own teeth, a lead line may develop along the 
gums, but similar pigmentation can occur after the absorption of 
mercury, bromine, silver, tellurium and iron. "Premature ageing" 
is often associated with advanced lead poisoning.
3. Chemical Diagnosis of Lead Poisoning
Lead exposure is said to occur when the level of lead in 
blood and urine exceeds the upper normal limit. Most authors 
do not state this limit but prefer instead to state a critical 
value beyond which the diagnosis of lead poisoning must be made. 
Kehoe (1961, Lee. 3) recognised this limit as occurring when the 
lead concentration in blood reached 80 ^ ig./l00 g. whole blood
4and when the urinary excretion of lead exceeded a value as low 
as 150 fig,/litre or as high as 240 fig./litre dependent on the 
urine sample. The Committee on Lead Poisoning (1943) recognised 
that the diagnosis of lead poisoning should be made when the 
urinary excretion of lead exceeded 150 yug./litre and that lead 
concentrations in excess of 70 yug./lOO ml. whole blood were 
indicative of recent lead exposure.
4. "Physiology" of Lead 
Absorption of Lead into the Body.
Lead can enter the body mainly by way of the respiratory 
tract, the alimentary tract and the skin.
In normal metabolism, most of the lead ingested in food 
and beverages passes along the alimentary tract and is excreted, 
mainly in faeces, with little or no absorption. Kehoe (1961) 
has shown that the introduction of lead compounds in solution 
into the alimentary tract, along with food and beverages, results 
in a limited degree of absorption of lead (8-12$) but that the 
inhalation of lead on a schedule corresponding to that of 
industry causes a prompt increase in the lead content of the 
tissue, blood and urine. The pulmonary absorption of lead is
. fairly efficient (30-50$).
The absorption of inorganic lead compounds through the 
skin is of little practical significance in the development of 
lead poisoning (Aub et al, 1926) but organic lead compounds, 
such as tetraethyl lead, can rapidly penetrate intact skin. 
Abrasion of the cutaneous epithelium may allow the passage of 
lead into the systemic circulation and lead on the hands may 
often be transferred to the mouth.
Transportation of Lead and its influence on Metabolism.
Lead is transported by the blood, reducing the erythrocyte 
life span by some specific mechanism which is not yet known.
At least 90$ of the lead is bound to red blood cells 
(Bambach et al, 1942). Young red blood cells are affected, 
probably in the marrow, before their formation is complete.
The inhibition of maturation of young red blood cells can be 
reflected by the rise in the percentage of basophilic stippled 
cells (Basophilic stippling of erythrocytes in peripheral blood 
is not specifically related to the absorption of abnormal 
quantities of lead since it occurs in many blood diseases).
As early as 1936, Watson suggested that porphyrinuria might
be a manifestation of an effect of lead on the synthesis of 
haemoglobin. He found that in the urine of patients suffering 
from lead intoxication, there were abnormally high concentrations 
of coproporphyrin, uroporphyrin and aminolaevulic acid.
These substances are precursors in the synthesis of haem (Table l) 
and can be measured quantitatively in the presence of urinary 
lead. Circulating lead is able to interfere in the early stages 
of porphyrin metabolism, probably due to its inhibitory action 
on -SH containing enzymes (Haeger-Aronsen, i960). This causes 
the urinary excretion of abnormal quantities of porphyrins-
The toxic effect of lead on young red blood cells and on 
the synthesis of haem, usually causes a secondary anaemia to 
develop.
Deposition of Lead.
The preliminary distribution of lead occurs via the 
general circulation to the kidneys, liver, lungs, spleen and 
muscles. But within a few days, the metal is redistributed 
and the major part is deposited in an inactive form in the flat 
bones (Aub et al, 1926). Lead can be removed from circulation 
and stored in bones due to deposition along with calcium when
Lead Poisoning
Glycine + Succinatei
6-aminolaevulic acid 1
Porphobilinogen
I
UroporphyrinogenJ '
Coproporphyrinogen
coproporphyrin III
Pro toporphyrin 
+
Iron1
Haem
TABLE 1
Possible sites of disturbed haem biosynthesis in 
lead poisoning#
a high calcium diet (e.g. milk) is maintained. In 
prolonged lead exposure there is generally a greater 
concentration of lead in the long bones (Kehoe, 1961, Lee 2). 
Excretion of Lead.
Lead is eliminated from the body via the intestines and 
kidney, the faecal excretion being far greater than that of 
urine. The major portion of faecal lead represents unabsorbed 
lead. Under normal conditions, during lead balance, the 
urinary excretion of inorganic lead is approximately 9/6 of the 
amount ingested (Kehoe, 1961, Lee 2). The cessation of 
exposure to lead is followed by a gradual excretory loss of 
lead from the body until, after a time appreciably longer 
than the period of exposure, the lead concentrations of 
excreta and blood fall back to normal levels.
Mobilisation of Body Lead.
In prolonged lead poisoning much lead is stored in the 
bones and this may be mobilised during metabolic stress, in 
acidosis due to lowering of blood pH (Aub et al, 1925) and 
inadvertently as a result of the administration of drugs, e.g. 
parathyroid extract (Hunter and Aub, 1927). This unexpected
release of lead may cause grave, even fatal illness. In 
prolonged renal failure, lead is also mobilised from the bones 
and released into the soft tissues ‘where it is accessible to 
chelation.
5. Chelation
The principle of chelation has found application in the 
treatment of lead poisoning. The role of chelating agents in 
this regard is to form ‘with the metal a diffusable complex ‘which 
is readily excreted from the body. A given chelating agent may 
have a strong affinity for a metal but be useless as a 
detoxifying agent for reasons of rapid metabolism in vivo, or 
toxicity to the patient requiring treatment. A number of 
chelating agents have been used to accelerate the excretion of 
lead from the body and one of the first to be used was B.A.L. 
B.A.L.
B.A.L. (British Anti-Lewisite, dimercaprol), a dithiol 
derivative of glycerol, came into use in 1945.
It was used as a complexing agent for both lead and copper.
CHt — CH —  coon
Pb
CH2_ CH ~  COOH
SH SH S
9However, not only is the intramuscular injection of the viscous 
liquid painful but the resulting lead complex is not very stable. 
After eight days of treatment in doses not greater than 2.5 mg./kg. 
body weight at one time, 4-6 times daily, 2 days rest is required. 
After a few years, it became evident that dimercaprol was not 
particularly suitable as an antidote to plumbism, since it is 
rapidly metabolised in vivo and also causes the development of 
skin rashes, fever and even coma in some patients. B.A.L. initially 
increases urinary lead excretion quite markedly but the effect 
wanes rapidly and the amount of lead mobilised is negligible. 
Apparently only lead in blood can be chelated by B.A.L., lead in 
bone and soft tissue being too firmly bound to be mobilised (Ryder 
and Kehoe, 1947). As the interest in B.A.L. waned, so the first 
favourable reports on E.D.T.A. were published (Bessman et al,
1952).
E.D.T.A.
E.D.T.A. (calcium disodium ethylenediaminetetraacetate, 
calcium disodium versenate) forms a water soluble, stable, non­
toxic complex with lead in blood and soft tissue and once bound, 
the chelate passes freely through most of the membranes of the
10
body, being excreted rapidly by the kidney. E.D.T.A. is not 
metabolised in the body.
CH, - C H *  C^2- CHa
NouOOC.CHz- N  N — CH2.COOMa- W aO O C .C H , —  N  N -C + ^ .C O O N c l
/  ^  /  \  Pb /  \ y  \
CH CflL CM*- ^  CM*- / \ CiHz
\ /  \  I I /  \  I
CO  O O — C.O C0 —  °  °  c o
. 14
In experiments with rats, 95-98% of labelled C versenate
appeared in the urine six hours after administration (Foreman et al,
1953)- However in patients with poor renal function, there is a
prolonged period of increased lead excretion. This keeps the
versenate circulating in the body for a much longer period causing
elevated blood lead levels (Rieders et al, 1955; Bessman and Layne,
1955). The administration of intravenous E.D.T.A. produces a
maximal excretion of urinary lead (Byers and Maloof, 1954) in
contrast to that of intramuscular E.D.T.A. Thus the former is
used mainly in the treatment of acute lead poisoning.
E.D.T.A. has however proved disappointing since severe cases
of renal damage, some of them fatal, occurred after excessive
dosage (Dudley et al, 1955; Foreman et al, 1956). It is not usual
to exceed a dose of lg. infused slowly at twelve hour intervals.
Courses of treatment must not last for more than five days but may
11
be repeated after one week.
Penicillamine
Penicillamine dimethyl cysteine) is so named because it
was the first crystalline substance, a primary amine, to be 
identified among the products of the hydrolysis of penicillin 
(Abraham et al, 1943).
CM3 H 
I I
CH. —  c —  o  -  c o o k
i i
5 H NHt
The asymmetric carbon atom means that penicillamine can exist 
in the D.,L or DL form. The D stereoisomer is used in the 
preparation of D penicillamine hydrochloride which is usually given 
orally in capsule form, each capsule containing 150 mg.
Penicillamine can also be given intravenously.
Penicillamine was first used by Walshe (1956) to chelete 
copper in the treatment of WilsonTs Disease. The copper-penicillamine 
chelate was very stable and greatly increased the urinary excretion 
of copper. In 1957, Boulding and Baker published a preliminary 
communication on the treatment of metal poisoning with penicillamine 
and stated that high doses (900 mg/day) of penicillamine may 
apparently be given for a long period with safety although no long­
term trials were quoted in the article. They showed that 900 mg. 
of penicillamine per day given to a lead smelter with a urinary 
lead excretion of 510 jug./litre, caused the urinary output to 
increase to 2000 jug. lead/litre. A female worker, exposed to lead 
vapours, with a urinary excretion of 530 jug. lead/litre after one 
month of E.D.T.A. therapy, was given 900 mg. penicillamine per day. 
On the 4th and 13th day of treatment, 1530 and 2000 jug. lead/litre 
urine were excreted respectively.
Oral pencillamine is rapidly absorbed from the small intestine. 
The effectiveness of penicillamine appears to be due in part 
to its relative stability to metabolic degradation, unlike its 
non-methylated parent compound cysteine (Aposhian, 1961). 
Penicillamine is able to form a firm, extremely soluble non-toxic 
complex with lead which is rapidly excreted by the kidney. The 
chelation of lead by penicillamine depends on the affinity of 
lead for the sulphydryl group and the complex may be one of the 
following:-
.In 1959> Fellers and Shahidi reported the onset of nephrotic 
syndrome in a 16 years old boy after eleven months continuous 
penicillamine treatment for ¥ilsonTs Disease. In the same year, 
Seignette and his co-workers published a paper comparing versenate 
and penicillamine in the treatment of one patient with Wilson1s 
Disease and one with lead poisoning. The patient with lead poisoning 
worked in an accumulator factory and had an average basal urinary 
lead excretion of 250 yug./24 hours. Daily 900 mg. doses of oral 
penicillamine given on four consecutive days raised the urinary 
excretion of lead to 2400, 2400, 1800 and 1800 yog./24 hours 
respectively. After a two day rest, 1000 mg. of intravenous E.D.T.A. 
per 24 hours was given daily for four consecutive days resulting in an 
excretion of 3500, 3500, 2000 and 2000 yng. of lead/24 hours respectively. 
The authors stated that one patient on continuous penicillamine 
therapy for eight months for the treatment of Wilson*s Disease,
showed no untoward reactions.
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6. Purpose of the Study
At the start of this work, penicillamine was not being generally 
used in the treatment of lead poisoning although its value in the 
treatment of Wilson1s Disease was recognised and Walshe (1956) had 
recommended its use for the treatment of gold and mercury poisoning. 
The following study was carried out with the object of l) determining 
the optimal dose of penicillamine required for the excretion of 
absorbed lead in cases of lead exposure and lead poisoning and
2) observing any side effects of penicillamine therapy if any, before
3) investigating whether a small prophylactic dose of penicillamine 
could usefully be given at regular intervals of time to those working 
under conditions of lead exposure, to discourage the accumulation of 
lead in the body.
7. Incidence of Lead Poisoning.
The incidence of lead poisoning is high in the following 
industries
a) In the manufacture of storage batteries, lead plates are made 
and covered in a paste of litharge, PbO. When the plates are dipped 
in dilute sulphuric acid, litharge is converted to lead sulphate.
15
b) In the building and breaking yards of ships and cars, lead
is present in pure or alloy form and as red lead, Pb 0 . The use
3 4
of oxyacetylene burners for cutting metals, often painted with red 
lead, and the use of high temperatures for welding, cause the 
formation of particulate lead and the volatilisation of lead 
compounds.
c) In the potteries and glass industries, red lead, litharge 
and white lead, 2PbC0 .Pb(OH) are used in making flint glasses 
and other forms of glass and also in making glazes for pottery.
8. Outline of Study
A short term study was carried out on nine patients with 
chronic or subacute lead intoxication to determine the effect of 
oral D -penicillamine, in varying doses, on the excretion of 
urinary lead, coproporphyrin (CP) and S aminolaevulic acid (ALA) 
as well as the clinical manifestations of the disease. The 
urinary excretion of CP (Chisholm and Harrison, 1956) and of ALA 
(Haeger-Aronsen, I960) provide sensitive biochemical indices of 
Tmetabolically activeT and presumably toxic lead. Blood lead, 
haemoglobin, reticulocyte count and punctate basophilia were also 
determined.
16
A long term study to determine the effect of long term 
oral penicillamine therapy was carried out for a period of 10 weeks 
on four oxy acetylene metal burners working in a shipbuilding yard and for 
a period of 16 weeks on one worker from an accumulator factory.
All five subjects showed clinical and biochemical evidence of lead 
intoxication.
17
Section All METHODS AND RESULTS
1. Haematological Methods.
Determination of urinary coproporphyrin and <9aminolaevul i c
acid
Haemoglobin was measured by the alkaline haematin method.
Other haematological values were obtained by standard methods 
(Dacie 1956):-
Reticulocytes.
Non-nucleated young red cells (or reticulocytes) are an 
intermediate form between the nucleated normoblast and normal red 
cell. They contain strands of nuclear material and stain with 
brilliant cresyl blue, showing a basket-like or reticulated 
appearance. In normal metabolism, a blood smear shows concentrations 
of 0.5 - 2# of reticulated cells.
Basophilic stippled cells
Punctate basophilia are red cells which show a stippled or 
dotted appearance. They may appear in blood as a result of lead 
exposure or due to certain blood disorders, but they are not present 
in normal blood metabolism. Stippled cells stain with Lofflerfs 
methylene blue and are counted under oil immersion lens, several 
fields being scanned.
18
Urinary coproporphyrin
This was determined using the ether and hydrochloric acid 
extraction method of Rimington (1961).
Urinary 8 aminolaevulic acid
This wad determined using the ion exchange resin technique 
of Mauzeralland Granick (1956).
2. Lead
Lead can be estimated quantitatively by the formation of 
its dithizonate complex or by its precipitation as the sulphide or 
chromate. Due to its extreme sensitivity, dithizone is the 
reagent of choice for the assay of microgram quantities of lead.
Dithizone (diphenylthiocarbazone), soluble in chloroform and 
carbon tetrachloride, forms a red dithizonate complex with lead.
Up to pH 12, dithizone acts as an acid with the H on the S removable 
and exists in equilibrium in both forms.
H S - C
/jN —  NH.
N = N.CtHs
/
MH - NH. CtWs
S =  C
19
If dithizone in form II is -written as then the reaction
with lead can be written as follows,
Pb'
2+
+ 2H2D2 ^  Pb (HDz) + 2H+
3k
the lead dithizonate complex having the form
r . «_
Dithizone can form stable complexes with many metals, e.g. 
Pb, Bi, Sn"^, Tl^, Pd, Hg, Ag, Cu, Au and Zn, under alkaline or
acid conditions. Each of these metals forms a dithizonate at a 
specific pH or pH range but if several of these metals are present 
in any one solution, more than one may be extracted into the 
dithizone-solvent layer.
Mechanism of Lead Extraction.
It is sometimes difficult to separate one metal in the presence 
of others and, to improve the separation factor, masking or 
sequestering agents are used. The masking agent usually forms 
water soluble complexes with the interfering metals in competition 
with the extracting agent. Masking agents (e.g. cyanide, citrate) 
form sufficiently strong complexes with interfering metals so that
20
the latter are prevented from reacting with the extracting agent
either altogether or at least until the pH is much higher than the
value needed for quantitative extraction of the metal of interest.
Very often the metal of interest also forms a complex with the
masking agent with the result that a somewhat higher pH range is
required for its extraction.
At pH 8-10 in the presence of cyanide, lead is quantitatively
extracted by dithizone, dissolved in chloroform (Dithizone-metal
complexes are more soluble in chloroform than carbon tetrachloride).
Under such conditions, stannous tin, thallium and bismuth are also
extracted and calcium and magnesium phosphates can interfere.
These phosphates can be masked by the addition of citric acid
(tartrate is less effective) before final adjustment of pH. No
2t + 2+
attempt was made at preliminary extraction of Sn T1 or Bi 
since these elements are not normally present in the body in 
appreciable amounts.
Determination of lead in urine, faeces and blood
Lead was estimated by the dithizone method of Gonzales et al 
(1954) as summarised below. This was later modified.
For blood, urine and tissue digests Gonzales et al recommended
a wet digest, to which was added 5 ml. of distilled water and 5 ml.
of saturated sodium chloride (NaCl) in 5$ hydrochloric acid (HCl)
for each 5 ml. of 36 N sulphuric acid used in the digestion
process. (The NaCl - HCl solution dissolved any insoluble lead
sulphate present). Any insoluble precipitate was filtered off
and the filter paper washed with 5 ml. of distilled water. After
the addition of 2 drops of phenol red indicator, the filtrate was
made alkaline with 14 N ammonium hydroxide. 5 ml. of 10$ citric
acid was added (to dissolve precipitated phosphates and prevent
their reprecipitation on adjustment of pH) and the pH adjusted to
7.6 with ammonium hydroxide. 2 ml. of 10% potassium cyanide (KCN)
was added and the solution transferred to a 250 ml. separating
funnel. The aqueous solution was shaken with small portions of
dithizone solution (15 mg./l chloroform, CHC1 ) and the CHC1 layers
3 3
combined and shaken with two 10 ml. portions of water, discarding 
the washings. The dithizone solution was then shaken with 20 ml. 
of stripping reagent ( 5 ml. 14 N ammonium hydroxide + 10 ml. 10$
KCN + 85 ml. water) and again washed with two 10 ml. volumes of water. 
The CHCl^ layer was run into a 50 ml. volumetric flask and the volume 
made up with CHCl^. The optical density of the red lead
22
dithizonate in CHC1 was read against a CHC1 blank in a
3 3
spectrophotometer at a wavelength of approximately 510 mjju
Preparation of lead-free glassware
Glassware was freed from lead by washing in the normal 
manner, immersing in 8 N nitric acid overnight and rinsing 
thoroughly with deionised water.
Extraction of lead from simple chemical solution
Initial steps were taken to draw up a calibration graph, 
relating the concentration of lead to the optical density.
y
Lead solutions in 250 ml conical flasks were adjusted to
pH 7.6 with 14 N ammonium hydroxide(NH OH) using 1% w/v phenol
4
red indicator and 2 ml 10$ KCN w/v was added. After transfer, 
with water washes, to a 250 ml. Quickfit separating funnel, the 
dark green dithizone solution (15 mg/l. CHCl^) was added from a 
burette and the separating funnel shaken vigorously for 30 seconds. 
If the CHCl^ layer was bright red (indicating saturation of existing 
dithizone), further dithizone was added and the funnel again 
shaken. A dull red CHCl^ layer with a dark tinge indicated the 
extraction of the major portion of lead. The CHCl^ layer was 
run off into a second separating funnel and 2-3 0.5 ml portions
23
of CHCl^ were added to the 1st separating funnel and drawn off
into the second separating funnel to wash 1 traces of lead
dithizonate from the outlet tube (This was done at every subsequent
CHC1 separation). The aqueous layer was shaken vigorously
with a further 3 nil of dithizone solution for 30 seconds. When
the phases had separated, the deep blue-green CHCl^ extract
(indicating the presence of excess unchelated dithizone) was run
off and combined with the first CHCl^ extract. The aqueous
layer was discarded. 15 ml of stripping reagent (100 ml. water +
5 ml 14 N. NH OH + 10 ml 10$ KCN) were added and the separating 
— 4
funnel shaken. If the aqueous layer was an ©range brown shade 
(indicating backwashing of large quantities of dithizone), the 
first separating funnel was rinsed out with deionised water and 
1-2 ml of CHCl^ run through the outlet tube (so that no water 
remained) before the CHCl^ layer was run into this separating 
funnel. This CHCl^ extract was shaken with a further 10 ml of 
stripping reagent when the aqueous layer should be pale yellow 
(discard) and the CHCl^ extract a clear bright red. After 
allowing the layers to separate and having checked that the 
outlet tube was dry (water disperses in CHCl^ to cause cloudiness),
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the CHCl^ extract was run off into a 50 ml. volumetric flask with the 
aid of a l^,f filter funnel. The solution was made up to the mark 
with CHCl^ and gently mixed before reading on the Hilger uvispek.
It was found that all standard stopcock greases - vaseline, 
apiezon, StevenTs rubber grease and silicone grease - were attacked 
by chloroform. For a short time, chloroform itself or a 
fluorohydrocarbon grease were used as lubricants. At room 
temperature, the fluorohydrocarbon grease was fairly hard and did not 
allow stopcocks to be turned easily, although it was otherwise 
satisfactory. These in turn were superseded by glycerol. Since 
glycerol mixes readily with water, stopcock glycerol must be renewed 
after each complete lead extraction. At all possible stages in 
the extraction of lead, aqueous solutions were not left in contact 
with stopcock glycerol, chloroform being added where required to 
prevent dissolution.
The stability of the lead dithizonate complex in chloroform 
with time was confirmed by checking the optical density over a two 
hour period, using optical cells fitted with ground glass stoppers 
to prevent evaporation of chloroform. If protected from light and 
evaporation, the lead dithizonate complex in chloroform is stable
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for at least a few days. The absorption maximum of lead 
dithizonate in chloroform was determined on the Hilger uvispek 
and found to be at 515-516 m^  (Fig. l) which is in agreement with 
the findings of Marmet (1958).
Calibration Graph.
A calibration graph was determined, using working solutions 
prepared from a standard lead acetate trihydrate solution of 
200 jig.lead/ml. The concentrations of lead as lead dithizonate 
in yag./50 ml. CHCl^ were plotted against the optical density 
reading obtained on the Hilger uvispek at wavelength 516 nyx 
and slit width 0.05 mm. Since dithizone and lead dithizonate in 
chloroform obey BeerTs Law if monochromatic light is used, the 
calibration graph (Fig. 2) was a straight line passing through the 
origin (tangent 0.00595).
3. Collection of urine, faecal and blood samples.
Urine
Lead-free polythene containers (cleaned as under glassware) 
were used for 24 hour urine collection. All collections contained 
thymol crystals as preservative and were kept cool and protected 
from light to avoid accelerating the breakdown of coproporphyrin
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Figure 1. Determination of the absorption maximum of 
lead dithizonate in chloroform on the Hilger uvispek.
and 8 amindaevulic acid. 30-100 ml. of urine were used for 
lead estimation.
Faeces.
Faecal samples were collected in lead free polythene 
containers and Lomogonired in glass honogonisers icy means of a 
TKecseise. 1 30-10 g. of the hoswgonatc, f or lead estimation, was
wemguod dirccLiy into a 10 cl. ujelaahl digestion flask.
Flood.
Approximately 10 ml. of verms.; blood was withdrawn for load 
estimation. The Flood was collected In a FeparLnised bottle and 
weighed directly into a 10 ml. diges u i on flask. (Blood was 
measured Fy volume initially. Talcing the mean specific gravity 
cf Flood was 1.06 (WintrlBe, lybi) all weights were converted to 
volumes of slood).
A. Concentration of Urine
In order to digest 100 ml. urine samples, initial concentration 
sad to Be effected. Lead can be precipitated from alkaline urine 
'ey addition of ammonium oxalate solution, lead oxalate being entrained 
along with calcium emulate. However, coi.iplexcd lead (e.g. lead 
penicillamine complex) would not do precipitated with inorganic lead.
As much as Lfiffo of the urinary lead can escape determination if the 
method of coprecipitation is used (Dinischiotu et al, I960). Other 
methods of concentration were tried.
Evaporation.
The most common method of concentrating large volumes of urine 
(up to 500 ml.) is by evaporation from an evaporating basin placed 
on a source of heat. This method was rejected as loss of sample 
through splashing and frothing was unavoidable.
Freeze Drying;.
100 ml. of urine was placed in a 500 ml. round-bottomed flask, 
resting in a mixture of solid carbon dioxide and alcohol, and the 
flask spun so that a thin layer of urine was frozen over its entire 
inside surface. "When this flask was connected to the freeze drying 
apparatus and a vacuum applied, the rate of loss of water was very 
slow, two 100 ml. samples being reduced to ca. 20 ml. in 7 hours. 
When a 5-10 ml. urine concentrate was obtained, it was difficult to 
remove the dried material completely from the inside of the flask 
with dilute acid and still keep the overall volume small. If a 
smaller flask (e.g. a 250 ml. round-bottomed flask) containing 
100 ml. of urine was used, the layer of frozen urine was so thick
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that frothing occurred on connecting to the vacuum, resulting in 
loss of material into the main frozen compartment of the freeze 
drying apparatus.
This method was rejected not only because it was time 
consuming but also because of transfer difficulties after con­
centration.
Evaporation under controlled conditions.
100 ml. of urine was pipetted into a 250 ml. conical flask 
and an anti-bumping device added, i.e. a bubble stick, which can 
also be used as a glass rod to facilitate liquid transfer. On 
placing on the hotplate, most urine samples frothed violently, 
becoming cloudy in the process. After experimentation with anti­
foam reagents (e.g. capryl alcohol and anti-foam A), it was found 
that the addition of 5 ml. of concentrated nitric acid caused the 
urine aliquot to clarify and boil without frothing. The increased 
acidity not only caused the oxidation and breakdown of some organic 
compounds (turning the urine black in the process) but helped to 
keep other substances in solution until, as the colour of the urine 
steadily lightened, the volume was reduced to 10-15 ml. The 
concentrate was poured into a 50 ml. kjeldahl digestion flask and
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the conical flask rinsed once with ion-free water. The washing 
was added to the kjeldahl flask. Two ml. l6N nitric acid were 
heated in the conical flask until nitric acid refluxed to the top 
of the flask (to remove any remaining lead) and the acid added to 
the kjeldahl. The conical flask was rinsed out four times with 
small portions of ion free water and the washings added to the 
kjeldahl flask.
5. Digestion
A wet digestion technique, using sulphuric and nitric acids, 
was employed in preference to incineration. The latter requires 
a higher temperature and may lead to loss of lead due to volatil­
isation.
Urine
The kjeldahl flask containing urine was placed in an electric
heating mantle and the volume rapidly reduced to ca. 5 ml. when
2^ ml. 36N sulphuric acid (H SO ) were added. (Failure to add
2 4
H SO to urine and faeces before dryness is reached results in the 
2 4
rapid emission of a column of dense white fumes, proceeded by 
spontaneous ignition, with consequent loss of the sample inside the 
kjeldahl.) Boiling was continued until the oxides of nitrogen
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were given off and charring occurred. 1I1J nitric acid was added 
dropwise as necessary to oxidise organic material. Digestion 
was complete only when on continued boiling, further charring did 
not occur. Small volumes of ion-free water were added to the 
kjeldahl and allowed to boil off to eliminate the last traces of 
nitric acid. Urine digests are colourless.
Faeces
The 30-40 g. homogenate was warmed in the presence of 3 ml. 
16N nitric acid and digested as above. Faecal digests are 
colourless.
Blood
A weighed sample was warmed in the presence of 3 ml. 16N
nitric acid and stirred frequently, by bubble stick, to stop foam
rising into the neck of the kjeldahl flask. Once boiling had
commenced, when the solution turned a greenish colour, 2j ml. of
36N H SO were cautiously added. If H SO is not present before 
2 4 2 4
the oxides of nitrogen are given off, a very violent reaction
occurs resulting in almost complete ejection of the sample from
the kjeldahl. A further 1 ml. of H SO may be required during
2 4
digestion. The digestion process was as before. Blood digests
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are straw yellow and have a trace of pale coloured precipitate 
present. (A light brown precipitate, the colour of which may 
be difficult to discharge is evidence of an incomplete digestion.)
Preparation of Digests for Extraction of Lead
"While blood, faecal and urine digests were still quite warm,
5 ml of ion-free water were cautiously added to each and the
contents of each kjeldahl vigorously swirled. For every 1 ml
of 36 N. H SO used in the digestion process, 2.5 ml of a solution 
2 4
of equal volumes of saturated sodium chloride and 5% v/v HCl were 
added. (This concentration of solution was sufficient to convert 
any insoluble lead sulphate into its soluble chloride form.)
All digests were left to stand overnight to allow complete 
precipitation of insoluble substances. A finely divided dense 
white precipitate formed in large amounts in faecal digests and 
in trace amounts, or not at all, in urine digests. A small 
quantity of this white solid was amassed by pooling precipitates 
collected after filtration of faecal digests. On cationic 
and anionic analysis of the precipitate, calcium and sulphate ions 
were identified. The presence of calcium sulphate in digests 
of material was confirmed by Sandell (1959 P 552).
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6. Extraction of Lead from Blood, Urine and Faecal Digests
The contents of each kjeldahl plus several washes with ion-free
water, were transferred to a 250 ml conical flask, filtering off
any heavy calcium sulphate precipitate with No 40 filter paper.
Two drops of phenol red indicator were added to the conical flask
and the solution made alkaline with 14 N.NH OH. 2^, 5, 12g ml
4
20$ citric acid (w/v) were added to the conical flasks containing
prepared digests of blood, urine and faeces respectively. The
pH was readjusted to 7.6 with NH OH and 2, 2 and 3 ml 10$ KCN
4
(w/v) were added for blood, urine and faecal samples respectively. 
Each solution was transferred with four water washes to a 250 ml 
Quickfit separating funnel which already contained 5-8 ml of 
dithizone (30 mg/litre CHCl^). Contact of glycerol, on the 
stopcocks, with aqueous solutions was avoided as much as 
possible, due to the solubility of glycerol in water. For 30 
seconds, the two phases were shaken vigorously. The layers 
were separated and the aqueous phase extracted with a further 
3 ml portion of dithizone. . The combined CHCl^ extracts 
were shaken with 15 ml and 10 ml volumes respectively of
stripping reagent (5 ml 14JJ.NH OH + 10 ml 10$ KCN (w/v) + 100 ml
4
water). If the concentration of lead dithizonate in the CHCl^
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extract was small, the extract was run off into a 25 ml volumetric 
flask in order to conserve CHCl^ and to give as high a reading 
for optical density as possible. 50 ml volumetric flasks were 
used only for high concentrations of extracted lead. A blank 
sample, containing the same amount of acid used in the digestion 
process, was treated in exactly the same way as the samples. The 
optical density of the lead solutions were read against chloroform 
on the uvispek at 516 mjx, and all readings adjusted to a 
theoretical 50 ml volume (linear graph). After subtraction 
of the blank, the lead concentrations were read directly from 
the calibration graph.
Formation of diphenvlthiocarbodiazone
Some blood samples, digested in the usual manner, gave a 
yellow chloroform layer on shaking with dithizone. This solution 
did not extract lead.
Dithizone can be oxidised under mild conditions to 
diphenylthiocarbodiazone,
^  tsl ■= Nl . C t ^ 5
s *= o
...N — N.
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a compound which is insoluble in alkaline or acidic solutions but 
which dissolves in chloroform giving a yellow or brown solution.
Since extraction of urine digests using the same dithizone 
solution gave no yellow chloroform extract, an oxidising agent 
was present in blood digests. No strong oxidising agent was 
present since the last traces of nitric acid had been removed.
Iron was the only element known to be present in large quantities 
(on addition of NaCl-HCl solution, the yellow colour of ferric 
chloride was observed) and it was complexed as a ferricyanide.
If the latter were able to oxidise dithizone, the removal of iron 
from the digest should result in normal extraction of lead.
The yellow chloroform extract and aqueous layer were 
transferred to a 250 ml conical flask and 2 ml of 10$ KCN added.
On acidifying with 1-2 ml of l6N nitric acid, the solution 
immediately turned green blue and a suspension of prussian blue 
(potassiiimAferrocyanide, KRt^Fe(CN)^"^ ) formed on heating. This 
was filtered off when the volume had reduced by half. The 
filtrate was boiled until the volume was ca. 5 ml and no nitric 
acid remained. The solution was again filtered to remove the
the usual manner, when only lead dithizonate was formed. The
before extracting with dithizone in
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lead content of a corresponding blank was estimated and subtracted.
This interference of iron was observed at the terminal stage 
of the study when blood lead values for normal subjects and those 
of a cross-section of workers in a ship-breaking yard (listed 
in Part B) were being determined. Fourteen samples in all were 
involved. Further blood samples were obtained for 7 of the 8 
workers from the ship breaking yard and these gave the normal 
coloured, chloroform extract due to lead dithizonate. Of the 
remaining 6, iron was removed (as prussian blue) in 4 of the 
samples, when a normal extraction of lead followed.
It would appear that the presence of a small concentration 
of a reducing agent during dithizone extraction may be of 
advantage.
7. Time required for digestion and extraction of lead
12-15 100 ml urine samples can be concentrated and 
transferred to kjeldahl flasks in 1-1^ hours. Once the charring 
stage of the digestion is reached (about 20 mins for urine and 
warmed blood samples and 1 hour for faecal samples), it takes almost 
one hour to complete the digestion of, for example 35 g of a 
faecal aliquot or 22 ml of blood. The time taken for complete
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digestion of urine samples after reaching the charring stage may 
vary from 10 minutes upwards depending on the initial urine 
concentration. Twelve digestions can be supervised at one time. 
If the concentration of other urine samples is to be effected 
at the same time, digestions can be made to proceed more slowly 
by reduction of mantle temperature.
The digests were grouped on the basis of the volume of 
nitric acid used in the digestion process (nitric acid being 
added to some where required), appropriate blanks were prepared 
and excess nitric acid was boiled off (30-45 minutes). Lead 
can be extracted from four solutions and the optical density 
of each read within one hour.
On an average, 12-15 samples can be concentrated, digested 
and their lead content estimated in two normal working days.
8. Precision of the method of lead assay
Six urine and six blood samples were analysed for lead 
and good agreement found (Table 2).
LEAD jig/100 ml
No. URINE BLOOD
1 84.2 63.4
2 82.1 64-5
3 84.7 63.9
4 81.7 65-4
5 84.4 63.0
6 84.8 6 4 . 7
MEAN 83.6 64.I
S.D. ±1.2 ±1.0
Table 2 Precision of determination 
of lead in urine and blood.
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Since the concentration of lead in faeces was generally low, 
liquification of faeces was carried out using the minimum volume of 
water. Faecal lead samples were always analysed in duplicate 
and the average result taken. The standard error calculated from 
double determinations on 26 faecal samples with lead concentrations 
between 6.9 and 411- jig per lOOg of homogenate (mean 96.8 jmg) 
was 7-7 JJg per lOOg, compared to a S.E. for 12 urine samples with 
lead concentrations between 3-9 and 83-0 jig/lOOml (mean 30-2 fig) 
of 0.7 /ig/l00ml.
The accuracy of the method was tested by adding known quantities 
of lead to 100 ml aliquots of urine. The results, given in 
Table 3, show that the method is useful for the determination of 
lead in biological material, 83 to 90$ of the total lead being 
recovered using two extractions with dithizone-
LEAD (jag)
PRESENT ADDED FOUND RECOVERED
83.1 10.0 93.6 10.5
83.1 20.0 101.0 17.9
83.1 40.0 119.0 35.9
4-47 10.0 12.70 8.23
4.47 20.0 21.43 16.96
4.47 40.0 38.00 33.53
Table 3 Recovery of lead added to 100 ml. 
aliquots of urine.
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9. Recovery of radioactive lead
210 , x
Pb (tx 19.4 years; was added to 100 ml urine samples which
2
were concentrated, digested and extracted for lead. The activity
of lead dithizonate in chloroform was determined by counting a 10 ml
aliquot in a Geiger Muller tube. The activity of lead recovered
210
however was only a fraction of that added. As Pb decays, a
daughter product bismuth is formed (tj^^Bi 2.6 x 10^ years). Lead
2
210 emits weak J3 -rays and some X-rays. Bismuth 210 however emits
210
very strong p> rays. Since an equilibrium mixture of Pb had been
210 210 
taken, Bi was also present but, contrary to expectation, Bi
had not extracted as a dithizonate along with lead.
210
The Pb solution was extracted with dithizone and 10 ml of
radioactive lead dithizonate in CHCl^ (2953 cpm) added to a 100 ml
urine sample. After concentration, digestion and extraction, the
total activity extracted from the urine two days later was 1663 cpm,
uncorrected for decay. Since chemical recoveries were greater than
this, no further attempts were made to recover radioactive lead.
210
It may be that counting Pb as a liquid sample on a |3 counter was 
210at fault. Pb as a precipitate is best counted on a windowless
counter e.g. a tritfcium counter or an X-ray spectrometer, none of 
which were available.
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10. Normal levels of lead, coproporphyrin, and 8 aminolaevu li c
acid
The levels of lead in blood and urine and of CP and ALA in 
urine were determined for a group of normal subjects (Table 4) and 
are summarised in Table 5. Some normal subjects did not wish to 
give blood.
The levels of blood lead and urine lead established in normal 
subjects (Table 5) are in agreement with those quoted by Goodman & 
Gillman (1955) (mean blood lead 30 fig/100g, mean urinary lead 27 Jig/ 
litre) and Kaplan & McDonald (1938) (mean blood lead 31 Jig/l00g).
The levels of urinary CP and ALA in normal subjects (Table 5) are 
also in agreement with those quoted by Zieve et al (1953) (mean for 
men and women 166 - 45 and 134 - 42 jig/day respectively) and Haeger- 
Aronsen (i960) (mean 0.29 - 0.14 mg/100 ml) respectively.
Kehoe (1961 Lee. l) stated that the lead content of random 
faecal samples obtained from two populations of normal subjects were
a) mean 0.232 mg, S.D. - 0.288 (447 subjects)
b) mean 0.39# mg, S.D. - 0.310 (102 subjects)
In ten normal subjects, he found the mean daily faecal excretion 
of lead to be 0.22 - 0.20 mg.
No. Sex Age Blood Lead 
u^.g/100 ml
Lead 
p.g/day
CP
/ig/day
ALA 
mg/daj
1 M 52 49.1 84.8 255 2.86
2 M 30 37.6 71.5 383 4.16
3 M 22 - 32.3 202 3.91
4 F 25 26.0 26.6 250 2.48
5 F 5 6 - 35.3 106 1.55
6 F 52 25.8 24.1 100 0.38
7 M 13 21.6 25.8 90.5 2.24
8 M 42 16.1 5.4 24.1 0.54
9 M 35 14.3 14.7 63.3 2.30
10 F 20 14.7 16.7 46.4 3.43
11 M 44 11.7 11.0 199 4.07
12 M 37 14.0 47.8 205 5.38
13 M 38 26.9 59.9 133 5.10
14 M 27 17.1 24.5 262 4.20
15 M 13 24.7 17.3 129 2.35
16 M 22 - 38.7 120 2.99
17 M 22 - 31.4 82 2.40
18 M 22 - 49.9 122 3.30
19 M 22 - 40.4 87 3.66
20 M 22 - 45.4 108 2.58
21 F 20 21.2 - - -
22 F 24 20.1 - - -
23 F 22 25.0 - - -
24 M 28 23.6 - - -
25 M 39 22.9 - - -
Table 4 Blood lead and urinary excretion of lead, coproporphyrin 
and 6 aminolaevulic acid in 25 normal subjects.
No* of Mean S.D. Bang#
subjects
Blood lead 18 22,9 (ig*/lOO ml
Urinary lead 20 /35«2 pg./day
J v23.3 jig./litre
Urinary coproporphyrin 20 |ig!^litre
Urinary 6-aminolaevulic /2.99 mg./day
acid '0*20 mg./lOO ml<
8*2 11.7 - 49.1
19.9 5.4 - 84.8
12.5 7.0 - 65.2
79.2 24.1 - 383.1
43.9 47.3 - 196.4
0*44 0.38* 5.38
0,08 0.02- 0.35
TABLE 5
Normal values of blood lead, and urinary lead, coproporphyrin and 
6-aminolaevulic acid.
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11. Clinical Cases
Cases 1-7 are o:xyacetylene metal-bumers -who have worked in 
a ship-breaking yard from 8 to 35 years. All of these subjects 
had been found to have increased coproporphyrin in their urine on 
routine testing.
Case 1. - Aged 42. Admitted to hospital two years
previously with acute abdominal colic. He still had intermittent 
abdominal pain. Hb 14 g./lOO ml., but punctate basophilia was 
present in the peripheral blood and bone-marrow.
Case 2. - Aged 55- Admitted to hospital in 1946, 1948*
and 1957 for treatment of lead-poisoning. On the present 
admission he complained of intermittent abdominal pain. Hb 13 g/ 
100 ml.
Case 3- - Aged 42. In the past year he had complained
of weakness of both hands and wrists. Hb 12.5 g/lOO ml.
Case 4- - Aged 52. Admitted to hospital in 1953* 1958,
and I960 for treatment of lead-poisoning. He had no symptoms 
on his present admission, but his haemoglobin level was 10g/
100 ml and the reticulocyte count k%-
Case 5- - Aged 60. No symptoms on admission. Hb
13 g/100 ml.
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Case 6. - Aged 50. Admitted in 1948, 1952, 1953, and
I960 for treatment of lead-poisoning. On his present admission 
he complained of intermittent epigastric and lower abdominal pain. 
Hb 15 g/100 ml.
Case 7- - Aged 60. Admitted on two previous occasions
(1948, 1954) for treatment of lead-poisoning. HB 12 g/100 ml.
He had no symptoms on admission.
Case 8. - A 48-year-old foreman of an accumulator factory
had been at this employment for 15 years. One year previously 
he had been treated with sodium calciumedetate because of right 
wrist and finger drop. He was readmitted on January 24, 1962, 
because of a recurrence of this paralysis. He felt reasonably 
well, though his haemoglobin level was 10 g/100 ml. In 1952 he 
had a skin rash after a penicillin injection.
Case 9- - A man aged 38 had been making lead ingots for
only six weeks. He presented with abdominal and lumbar pain, 
vomiting, and constipation. On examination he had a ,fblue line11 
at the gum-tooth margin. Hb 11 g/100 ml. Reticulocyte count 
% m Punctate basophilia was noted in bone-marrow smears but 
not in his peripheral blood.
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12. Scheme of therapeutic investigation: Short-term trial
of penicillamine
This was carried out in hospital in a metabolic ward. All 
patients had a pretreatment period of 7 to 12 days for the measure' 
ment of the daily output of urinary and/or faecal lead, urinary 
CP and ALA. Haematological and some blood lead estimations were 
made. Cases 1 and 2 had seven day courses of penicillamine of 
900 mg/day. Case 9 had two separate courses of penicillamine of 
900 mg/day, each course lasting seven days. Cases 3 and 4 had 
900 mg of penicillamine daily for 4 days, followed by 1500 mg 
daily for four days. Cases 5* 6 and 7 had 1500 mg daily for 
seven days. These details are listed in Table 6.
Case
Peni­
cillamine 
(mg. 'day)
Mean
Lead
(/ig.'day)
Mean 
Coproporphy­
rin (#jg./day)
Mean d- 
Aminolaevulic 
Acid (mg./day)
Dose Duration Before During Before During Before During
1
»{
6
7
8
9{
900
900
900
1.500 
900
1.500
1.500
1.500
1.500 
150- 
1,200
900
900
7 days 
7 „
4 „
4 „
4 „
4
7 „
7 ,.
7 „ 
23 „
7
7 „
398
218
192
141
202
149
200
242
876
939
855
796
1.136
738
946
1,033
521
746
756
1,261
975
588
1,269
786
722
612
499
878
1.502
632
377
211
983
133
606
(98
224
159
158
276
851
400
400
25-5
31-5
28-8
22-6
23-2
12-9
43-8
64-9
29-5
10-8
17-1
25-8
12-8
19-7
12-2
11-9
5-1
6 0
11-7
36-4
16-5
Table 6 Short-term trial. Summary of the mean 
urinary lead, coproporphyrin and 
S -aminolaevulic acid in Cases 1-9 
before and during treatment.
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13. Results of the Short-term Trial
In every patient prior to treatment -with penicillamine the 
values of urinary lead, CP and ALA, were greatly in excess of 
normal levels. On the other hand, the faecal lead values prior 
to treatment fell (Case l) or lay (Cases 2-7) within the normal 
range (Kehoe 1961 Lee l). This is explained by the fact that 
faecal lead excretion is not a satisfactory index of lead intoxi­
cation, where the exposure is mainly due to the vapours of lead, 
and that the faecal lead values approach normal within a few days 
after the termination of such exposure. (Goodman & Gillman, 1955)
Clinical Course
There was clinical improvement during treatment in each of 
the patients who had symptoms. In Cases 1, 2, and 6 there was an 
absence of abdominal pain. Case 3 claimed that there was a return 
of strength to his hands. In Case 8 there was improvement in 
muscle power after two weeks of treatment. Complete return of 
power occurred after a longer course of penicillamine. In Case 9 
there was a rapid cessation of abdominal pain, vomiting, and 
constipation within three days of the beginning of penicillamine 
treatment.
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Urine
The highest basal urinary lead excretion recorded amongst 
these nine patients was that of the patient suffering from acute 
lead intoxication (Case 9). He was admitted to hospital prior to 
the lead study and was given penicillamine therapy for two periods, 
each of seven days, the results of the second period of which are 
shown in Fig. 3* The lead excretion was determined on the 
remaining available urine samples and a marked rise in lead ex­
cretion was noted on commencement of oral penicillamine. Day 14 
marked the end of the first course of penicillamine and from day 
15, the urinary excretion of ALA steadily increased until its 
value was doubled. CP, on the other hand, rose immediately to 
a high level on discontinuation of penicillamine therapy. On 
resumption of penicillamine treatment, the excretion of ALA decreased 
slowly while that of CP showed an immediate pronounced fall. On 
the 30th day, the urinary excretion of CP had fallen within the 
normal range while the urinary excretion of both ALA and lead were 
still 4 times the upper normal value.
When 900 mg of penicillamine was given daily to Cases 1 and 
2, there was a significant rise in the urinary lead excretion, 
which declined slowly after the initial high output (Figs. 4 and 5)-
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Figure 3» Short-term Trial, Excretion of urinary lead, 
coproporphyrin and & -aininolaevulic acid in Case 9 before 
and during treatment with oral penicillamine, 9C0mg 
daily for* eight days (second course).
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Figure 4. Short-term Trial. Excretion of faecal lead 
and urinary lead, coproporphyrin and <f-aminolaevulic 
acid in Case 1 before and during treatment with oral 
penicillamine, 900mg daily for seven days.
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On admittance to hospital, the urinary excretions of CP were high 
but during the 7 pre-treatment days, they fell of their own accord 
due to termination of lead exposure. The excretion of ALA however 
remained fairly high during this period. During the period of 
increased lead excretion, urinary excretion of CP and ALA decreased 
markedly, tending towards but not reaching normal levels.
In Cases 3 and 4* the administration of 1500 mg of penicill­
amine daily after an initial 4 day course of 900 mg of penicillamine 
daily caused a further increase in lead excretion, with a more 
pronounced decline thereafter than that recorded with 900 mg (Figs.
6 and 7). In Case 3, the excretion of CP decreased dramatically 
with the 1500 mg dose of penicillamine. Once more, the excretion 
of ALA decreased at a slower pace than that of CP under the 
influence of increased lead excretion.
On the second day of treatment with 1500 mg of penicillamine 
per day, a peak excretion of urinary lead was recorded in Cases 5,
6 and 7 (Figs. 8, 9 and 10). The decline in lead excretion 
following this peak output was not as marked as it had been in 
Cases 3 and 4 (Figs. 6 and 7)• Over the seven days of penicill­
amine therapy, the excretion of urinary CP and ALA decreased,
attaining normal values in all three cases on the final day.
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Figure 6 . Short-term Trial. Excretion of faecal lead 
and urinary lead, coproporphyrin and rf-aminolaevulic 
acid in Case 3 before and during treatment with oral 
penicillamine, 900mg daily for four days and 1500mg 
daily for four days.
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Figure 7. Short-term Trial. Excretion of faecal lead 
and urinary lead, coproporphyrin and a— aminolaevulic 
acid in Case 4 before and during treatment with oral 
penicillamine, 900mg daily for four days and 1500mg 
daily for four days.
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Figure 8 . Short-term Trial, Excretion of* faecal lead 
and urinar; lead, coproporphyrin and S —aminolaevulic 
acid in Case 5 before and during treatment with oral 
penicillamine, 1500mg daily for seven days.
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Figure 9. Short-term Trial. Excretion of faecal lead 
and urinary lead, coproporphyrin and &-aminolaevulic 
acid in Case 6 before and during treatment with oral 
penicillamine, 1500mg daily for seven days.
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Figure 10. Short-term Trial, Excretion of faecal lead 
and urinary lend, coproporphyrin and <f-aminolaevulic 
acid in Case 7 before and during treatment with oral 
penicillamine, 1500 mg. daily for seven days.
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In view of the previous history of penicillin sensitivity 
in Case 8^  penicillamine was given in gradually ascending dosage 
from 150 to 1200 mg/day. After a minimum single dose of 150 ing; 
runicill.'uulne was given in divided dosage thrice dally. As low 
a dose as. 000 reg/day of penicillamine caused immediate rise in 
the urinary excretion of lead (Fig. 11). Each increase in the 
daily dose of penicillamine brought about a. corresponding increment 
’ r urinary load excretion until,, at 900 mg oh renici llamine por 
day, the nsixlmum level of excretion of load was reached,, doses of 
1050 and 1200 ng of penicillamine inducing no further increase in 
1ead excretion. It is notaolc that excessive load v/as still 
being excreted in the urine when the levels of urinary CP and ALA 
sad returned to normal. During the protroatr.ont por-od,, the 
urinary excretion of both CP and ALA do els red slightly, due to 
mho j anient me lunger ooirr eescosod to lead. The .level of urinary 
lead cxerctiai, a.s usual, did non fall during ur.Ls period of non- 
cxposure .
f oiconing, 7 of them, presented vans an average Isos uraary 
excretion of lead of about 200 ^ug/day. ■nor - nan .'in average 
basal urinary load excron ion of twice this value. Toe nation o
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Figure 11. Short-term Trial. Excretion of urinary lead, 
coproporphyrin and & —aminolaevulic acid in Case 8 before 
and during treatment with increasing doses of oral 
penicillamine,
47
with acute lead intoxication,, Case 1, excreted an average of 8r/6 jag 
Pb/21 hour urine during a non-treatment period.
Faeces
There was no significant rise in faecal lead excretion after 
the administration of penicillamine in Cases 1-7 (Table 1, Figs. 4-
10). All faecal values^ with the exception of Case 1_, lay within 
the normal range on admittance to hospital^ but after 4 days in 
hospital and of non-exposure to lead,, the faecal lead excretion of 
Case 1 also fell to normal values. During the period of study, 
there was a decline in most cases in faecal lead excretion comparing 
the pretreatment and treatment values as seen in Table 7-
Blood
i) Blood lead
There was a fall in blood lead in Cases 1 , 1 , 1  and 8 (Figs. 12 
and 13) comparing the levels before and during penicillamine treat­
ment (Table 8).
Cases 3 and 4 had blood lead values of 84 and 77 J^-s/lOO ml 
respectively on the final day of penicillamine therapy. No pjre- 
treatment values were obtained.
BEFORE TREATMENT DURING TREATMENT
Case
No. No. of days 
collected
Mean output 
/ig/ day
No. of days 
collected
Mean output 
/ig/ day
1 1+ 603 6 2^3
2 k 316 6 218
3 3 59 8 66
k 6 102 8 78
5 6 153 7 93
6 5 1^9 2 25^
T k 171 7 1U5
Table 7 Short-term trial. Facea L excretion of lead .In Cases
1-7 before and during tre;atment with penicwllanine.
BEFORE TREATMENT DURING TREATMENT
Case
No. No. of Mean blood 
samples lead Qug/100 ml)
No. of 
samples
hear: blood 
lead (jng/100 ml,
5 5 67.6 8 57.7
6 2 82.7 5 77-0
T 5 83.^ 8 76.0
8 2 151.7 3 89-9
Table o Short-term trial. Mean blood load in Caooo 5 
before and during treatment vrith porn.e^ l-Lamino
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Figure 12. Blood le^d in Cases 5» 6 and 7 before 
and during treatment with oral penicillamine, 1500 
^g. daily for seven days.
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Figure 13. Blood lead in Case 8 before ann during 
treatment with increasing doses of oral penicillamine.
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ii) Lead, in plasma or erythrocytes?
Blood samples were obtained from Case 5 and another patient, 
neither of whom were being given penicillamine. After deter­
mination of P.C.V., the blood was centrifuged, the plasma drawn 
off and its volume measured. The red blood cells were gently 
mixed with a volume of normal saline to remove any traces of 
plasma. After centrifuging and discarding the saline, the r.b.cTs 
were measured in a 10 ml measuring cylinder. The lead content 
of plasma and erythrocytes were determined. In both cases, there 
was no lead in the plasma. Using the P.C.V., the total lead per 
100 ml of whole blood was calculated and found to be 73.8 and 54.3 fig  
for Case 5 and the other patient respectively.
iii) Haemoglobin
Haemoglobin values determined on admission to hospital and 
stated under clinical cases, were low in Cases l+, 8 and 9.
iv) Punctate basophilia
Stippled cells were present in the peripheral blood of Cases 
4 and 8, in bone marrow only in Case 9* and in peripheral blood and 
bone marrow in Case 1. (Cases 1 and 9 had high levels of basal 
urinary lead excretion. Case 8 suffered from wrist drop and Case 
K) like Case 8, had marked anaemia.)
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v) Reticulocyte Count
On admission to hospital, the reticulocyte count was deter­
mined for each patient. Cases 2, 3, 6 and 7 had a reticulocyte 
count of less than 2%. Cases 1, 4^  5> 8, 9 had a reticulocyte
count of 2 .5 )  h 3 2, 6 and 3% respectively.
Cases 1, 4, 8, and 9 had values greater than normal.
14. Scheme of Therapeutic Investigation: Long-term Trial of
Penicillamine
A long-term trial of penicillamine lasting ten weeks was 
carried out on Cases 1, 2, 33 and 4 while they were at work in the 
ship-breaking yard. This long-term trial was begun three months 
after the end of the short-term trial in Cases 1 and 2 and 10 days
after the end of the short-term trial in Cases 3 and 4. Before
treatment was begun all of these men were anaemic, with haemoglobin 
levels of 11.4, 10.2, 10.8, and 8.9 g/100 ml respectively. In 
addition all had an increased excretion of lead in the urine. Cases 
1 and 2 had intermittent abdominal pain. Case 3 complained of weak­
ness of his hands and wrists. Case 4 had no symptoms, although he 
was in fact the most anaemic of the group. Penicillamine was given 
in a dosage of 300 mg daily for three weeks and then 600 mg daily 
for the remaining seven weeks. The capsules, each containing 130
50
mg of penicillamine, were presented each morning to the men by a 
medical orderly and taken in divided dosage twice daily. On Friday 
sufficient capsules were given to suffice over the week-end.
Case 8 remained anaemic after his initial treatment. He 
had developed paresis of his right hand on two occasions within one 
year and yet was determined to return to his work as a foreman in 
an accumulator factory. For these reasons he was given a course of
penicillamine, 600 mg/day for a period of four months while he was 
at work.
In Cases 1, 2, 3> and A, overnight urine specimens (volume ca.
500 ml) were collected twice weekly and tested for lead, copro­
porphyrin, and & -aminolaevulic acid. In Case 8 urine specimens 
were tested every four weeks. In a~l^ five cases haemoglobin levels 
and reticulocytes were assessed every four weeks.
Throughout these trials the subjects continued to use a protec­
tive mask in the same way as they had previously done.
15. Results of the Long-term Trial
In Cases 1, 2, 3 and 1+ there was no significant response to 
300 mg of penicillamine daily (Figs. 11-17)» must be repeated
that this trial was carried out while the subjects were at work and 
exposed to further lead intoxication. Although the excretion of
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Figure 14. Long-term Trial. Excretion of urinary lead, 
coproporphyrin and cT-aminolaevulic acid in Case 1 before, 
during and after treatment with oral penicillamine, 300 
nig. daily for three weeks and 600 mg. daily for seven 
weeks.
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Figure 15. Long-term Trial. Excretion of urinary lea.d, 
copropornhyrin and <£—aminolaevnlic acid in Case 2 before, 
during and after treatment with oral penicillamine, 300 
Mg. daily for three weeks and 600 mg. daily for seven 
weeks.
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Figure 10. Long-term Trial. Excretion of urinary lead, 
coproporphyrin and ^-aminolaevulic acid in Case 3 "before, 
during and after treatment with oral penicillamine, 300 
mg. daily fo^ th^ee weeks ant 600 mg. daily for aeven 
vce> ••.
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Figure 17, Long-term Trial. Excretion of urinary lead, 
coproporphyrin and (f—aminolaevulic acid in Case 4 before, 
ouring and after treatment with oral penicillamine, 300 
Mg. daily for three weeks and 600 mg. daily for seven 
weeks.
urinary lead rose sharply in Case 2 and to a lesser extent in 
Case 3 on commencement of treatment with 300 mg of penicillamine 
per day., there was no significant change in the excretion of CP 
and ALA in all four cases. After throe weeks, the dose of peni­
cillamine was raised to 600 mg/day. Case .7. showed a significant 
rise in urinary lead excretion. This began to decline at day 
140 simultaneously with a decrease in the urinary excretion of CP 
.and ALA. In Case 2, the urinary lead excretion, which had shown 
a significant increase on 300 mg of penicillamine therapy., did not 
alter when the dose was raised to 600 mg/day. The excretion of 
CF and AJLA however showed a narked decrease on commencement of 
600 rag of penicillamine daily. On increasing the dose of 
pen!cilLimine, the urinary lead excretion of Case 3 rose for 
the second time. Once again., the excretion of CP rind ALA fell 
only during the period when 600 mg of penicillamine was being 
given. In Case 4, there was a significant rise in urinary lead 
excretion only with 600 mg of nenicillanine daily. After the 
-mutual high output, the urinary lead excretion began to decrease, 
accompanied by a corresponding decrease in the excretion of ALA.
In all 4 cases, 500 mg of peril cill awl no -was required to 
cause a decrease in the urinary excretion of CP and ALA although
smaller doses (e.g. J00 mg) may still cause a significant increase 
in the excretion of urinary lead.
At the end of the seven week course of 600 mg of poniei Llarrj.no 
dally , the urinary excretion of CP and ALA in Cas.es '1-4 had fallen 
to normal levels. In all cases, the urinary lead excretion after 
f •on! cllluniino therapy was, as expected, slight Ly lower than that 
before ponieillarj.no therapy but within 1-6 weeks of dir,continuatLon 
:‘f oonl.elllnmino, there was a gradual rise in the urinary excretion 
of lead, 0P and ALA in Cases 1, P. and p.
After treatment with penicillamine, the haemoglobin levels in 
Car,os I, A, 3 and 3 rose ho 13.1, 11.3- 13-3- raid 1.1. g/lOC ml as 
• prepared with 11.4, 10.2, 10.3, asd 3.9 g/lOO ml rc;soecLively before 
treatment (Fig. 13). Cases, ! and 2 claimed that their abdominal 
pain had ceased, end 'Case; p stated that Ids wrists mid hands had 
regained tnei r former strength. Throughout these months of treat­
ment with pen 1 c LiLanin o none of these four subjects had any untoward 
effocp of drug therapy; hr. [.articular, the urrnc was free of 
: snicin .at the end of the hroahmont period.
■Case 3, after the. Initial, sbjrt-tor::. treatment, had only 
tl.-gni residual wemkness of Inis rirlit mwi, out no was stall anaemic 
(ho 10.4 g/100 ml). After four months of treatment with 60G mg
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Figure 18. Haemoglobin levels in Cases 1 , 2 , 3 , 4 
and 8 before, during and after long-term trials of 
penicillamine.
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penicillamine/day he had normal power in his hand and his haemo­
globin level had risen to 13.8 g/lOO ml. Throughout this period, 
the urinary lead excretion remained fairly high (Table 9). Nine 
weeks after leaving hospital (i.e. day 111), the urinary excretion 
of CP reverted to abnormal values. On day 42, the final day in 
hospital, Case 8 had a normal urinary excretion of 0.18 mg ALA/lOO ml. 
On day 54j while on penicillamine therapy of 600 mg per day, the
excretion of ALA had risen to the abnormal value of 0.58 mg/lOO ml
urine. At the end of the four month period, the blood lead had not 
been lowered (73-5 /ig/100 ml on day l6l compared to 70.1 jig/100 ml 
on day 39., i.e. 3 days before the start of the 4 month penicillamine 
course). Although without symptoms at the end of the 4 months1 
treatment this patient was found to have protein in his urine (0.4 g/
100 ml). After a few days, this fell to 0.1 g/100 ml but two months
after the cessation of penicillamine treatment, he continued to 
excrete about 0.1$ protein in his urine. He has maintained the 
power of his right hand and his haemoglobin level has remained normal. 
His exposure to lead has been discontinued.
Day
5b 89 111 138 161
Blood Lead
p.g/100 ml ” “ “ 73.5
Urinary Lead
r l li.r, M S  63S - 272
“ 9 SO SOS S92
Urinary ALA „ .
mg/100 ml O.58 - 1.72 1.60
Table 9 Long-term trial. Blood lead and urinary excretion of 
lead, coproporphyrin and S  aminolaevulic acid in Case 8 
during treatment •with oral penicillamine, 600 mg daily 
for four months.
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Section A.Ill 
Discussion
These studies have shewn that penicillamine, given orally, 
causes a prompt and marked excretion of urinary lead in patients 
with lead intoxication. A dose of 300 mg/day is sufficient to 
effect a significant lead excretion, provided the patient is no 
longer exposed to further lead intoxication, but marked excretion 
was induced by daily doses of 900 to 1,500 mg. (Fig.13)
The increased lead excretion was not effected through the faecal 
route. There was a fall in the blood-lead levels with treat­
ment and also a marked fall in the urinary levels of copro­
porphyrin and of 8 -aininolaevulic acid. The urinary excretions 
of these substances are thought to be sensitive indices of 
metabolically active lead (Haeger-Aronsen, I960). For this 
reason it is of considerable interest that the continued 
administration of penicillamine in Case 8 yielded a marked 
excretion of lead at a time when the urinary levels of copro-
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Figure 19. Comparison of the excretion of urinary 
lead, coproporphyrin and a-amino1aevUlic acid in Cases 
1“8 before and during treatment with oral penicillamine.
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porphyrin and S -aminolaevulic acid were normal. This 
suggests that penicillamine can mobilize stored lead for ex­
cretion.
There was a substantial increase in the haemoglobin levels 
in Cases 1, 2, 3, k, and 8 after long-term treatment from two 
to four months, even though these patients were still engaged 
in a lead-exposed occupation. The anaemia of lead-poisoning 
is due to two main factors. Firstly, an inhibition of haem 
synthesis, at several stages in the formation of haem and 
especially in the final phase of iron incorporation into the 
haem or haemoglobin molecules (Goldberg et al., 1956).
There is in addition a haemolytic factor (Wintrobe, 1961); 
a significant reduction in the erythrocyte life-span has been 
demonstrated, returning to normal after treatment (Goldberg, 
I960). Both of these effects are probably caused by a direct 
effect of lead on the biosynthesis of haemoglobin in the 
marrow and on the erythrocyte membrane respectively, and it 
is therefore not surprising that the simple removal of body
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lead should prompt an increase in the haemoglobin level. It 
is notable, however, that the relief of the anaemia was a 
gradual process over a period of two to four months. There 
was, in addition, a complete return of motor power to the right 
hand of Case 8 after a prolonged course of treatment, as well 
as a rapid cessation of abdominal pain, vomiting, and constipa­
tion in Case 9-
The pathogenesis of the neurological and abdominal 
symptoms in lead-poisoning is unknown. It is possible that 
the mechanism of production of these symptoms has a common 
biochemical pathway with that of acute intermittent porphyria 
(Goldberg et al., 1962). In both diseases there is a marked 
increase in the excretion of S -aminolaevulic acid. In 
lead-poisoning these symptoms are relieved by the removal of 
lead from the body by chelators of lead, such as sodium 
calciumedetate or penicillamine. Peters et al. (1957) have 
suggested that in their experience the symptoms of acute 
intermittent porphyria may also be relieved by chelating 
agents. There is, however, insufficient confirmatory evidence 
on this point.
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The studies on the long-term administration of penicillamine 
are of practical importance to the prophylaxis of lead-poisoning.
The best prophylaxis is, of course, prevention of entrance of the 
metal into the body by the established methods of industrial hygiene. 
Nevertheless, it must be accepted that some lead-workers find it 
impossible to wear a mask constantly; nor is the general standard 
of industrial hygienic equipment of such efficiency as to allow us 
to ignore the drug prophylaxis of lead intoxication. Penicillamine 
has now been used in the long-term treatment of Wilson’s disease 
for six years; Walshe (1962), whose experience in this field is 
extensive, has found this drug to be particularly non-toxic. There 
was no evidence, in his experience, of renal damage with the D isomer 
of penicillamine, which is that used in this country. Scheinberg 
(1962), who has also had considerable experience in the treatment 
of Wilson’s disease with penicillamine, has not found proteinuria 
in any of his patients which could be attributed to the drug.
Fellers and Shahidi (1959) noted the onset of frank nephrotic syn­
drome in a male patient of 16 years who had been given 2 g of 
penicillamine a day for nine months. The clinical manifestations, 
including the proteinuria, disappeared after the withdrawal of 
the drug. Our experience of Case 8 has shown that, in lead-poisoning,
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penicillamine given over a period of four months can be nephro­
toxic.
In the present studies it has been shown that 600 mg of 
penicillamine a day orally is an effective dose. Mien given over 
a period of two to four months to lead-workers it has induced a 
marked lead excretion, a return to normal levels of urinary 
coproporphyrin and -aminolaevulic acid, and a rise of the haemo­
globin level. Case 8 had a history of skin reaction following 
a penicillin injection 10 years previously. With a gradually 
increasing dosage of penicillamine, no skin reaction occurred, but 
at the end of this period he developed protein in his urine, with 
other evidence of renal damage. This evidence must, at present, 
contraindicate the possible use of penicillamine on a long-term 
basis in lead-poisoning; nevertheless, penicillamine is a useful 
drug in short-term courses of not more than four weeks. Subjects 
showing early clinical evidence of lead intoxication - for example, 
with mild anaemia or occasional gastro-intestinal symptoms - might 
receive oral penicillamine while at home or after being transferred 
to work not involving the risk of exposure to lead. The urine 
should be tested for protein at least once weekly. Any worker 
with a more severe degree of lead—poisoning should be treated in
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hospital. It should again be emphasized that the established 
protective measures form the best prophylaxis. In addition to 
these industrial indications for penicillamine the drug has obvious 
advantages over a parenteral lead chelator in the treatment of 
lead intoxication in children.
Summary
D  -Penicillamine, given orally in doses of 600 to 1,500 mg/day, 
induced a marked excretion of urinary lead in nine patients 'with 
subacute or chronic lead intoxication. There was a concurrent fall 
in the urinary coproporphyrin and & -aminolaevulic acid levels and 
in the level of lead in the blood. The route of excretion was 
entirely by way of the urine.
Five lead-exposed subjects, while working in a shipbreaking 
yard or in an accumulator factory, were given oral penicillamine 
for periods of from two to four months. There was a persistent 
excretion of urinary lead, a fall in the urinary coproporphyrin 
and -aminolaevulic acid to normal levels, a rise in the haemo­
globin levels, and a relief of neurological or abdominal symptoms. 
The effective dose of penicillamine for this trial was 600 mg/day. 
One patient developed proteinuria after four months of penicillamine
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treatment. For this reason routine testing for proteinuria should 
be carried out in patients during treatment; the duration of a 
single course of penicillamine should not exceed four weeks; patients 
during treatment should be removed from a lead-exposed environment.
It is suggested that, with these stipulations, oral penicill­
amine is a useful drug in the treatment of lead-poisoning and may be 
of value in the treatment of lead-poisoning in children.
PART B. SURVEY OF INDUSTRIAL 
READ EXPOSURE
Section B.I INTRODUCTION
In Britain, most cases of lead poisoning originate in lead 
industries such as ship-building and ship-breaking and in factories 
where batteries and accumulators are made. On such industrial 
sites or in such factories, the exposure to lead dust and fumes is 
not necessarily confined to those actively working with lead.
Varying degrees of exposure are suffered by lead workers and their 
co-workers in industry. A survey was carried out in the same 
ship-breaking yard which had employed 7 of the patients studied in 
the previous section. Haematological tests, blood lead and urinary 
lead7 coproporphyrin and <S -aminolaevulic acid were determined in 
all of the selected subjects where possible.
1. Purpose of the Study
The purpose of the study was to determine:- l) relative 
sensitivity of the above tests in detecting industrial lead exposure 
2) the relative dangers of lead exposure to different groups of 
workers on the one site; 3) if a relationship existed between 
the clinical manifestations of the disease and its chemistry, i.e. 
whether a particular symptom appeared when a certain threshold value 
of one of the above tests was reached.
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2. Relative sensitivity of some tests for lead poisoning
Of the tests carried out, the relative sensitivity of some have 
already been assessed. In an article published in 1961, Shrand 
drew up a table of diagnostic aids to lead poisoning. A part of 
this table only is reproduced below since the remainder is applicable 
particularly to children.
Diagnostic Aid Probability of a -Hve Result
Coproporphyrinuria
(ether + HC1 extraction)
Urinary ALA
Basophilic stippling
Urinary ALA is cited as a sensitive indice of exposure to lead 
due to the increase in excretion of urinary ALA varying directly 
with the degree of exposure to lead. The increase in excretion of 
ALA is said usually to procede. that of CP (Haeger Aronsen, I960).
There has been doubt as to the value of the test for punctate 
basophilia which is one of the routine tests for suspected lead 
poisoning. This test was included in the survey. If there proved 
to be as low a probability of a +ve result as 18$, then such a test
would not be suited to routine industrial inspection.
100
100
18
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3. Routine screening of workers
In the ship-breaking yard, routine medical inspection of each 
burner was performed, on an average of once per fortnight, by a 
visiting doctor. This screening may take the form of a simple 
checkover and a blood sample and/or spot urine sample may be taken 
for haemoglobin and CP estimation respectively. The physical 
appearance (e.g. pallor) of the worker may well give an indication 
of lead exposure if the worker has been known to the doctor for a 
period of time.
All burners in this ship-breaking yard were supplied by the 
firm with protective masks, the filter of which, at the nose-mouth 
area, was renewed freqeuntly. The filter gave protection only 
against dust. Although the majority of burners found it impossible 
to wear the mast constantly, especially in warm weather, all agreed 
that masks were worn for certain tasks involving a greater degree 
of lead exposure and as much as possible at all other times. The 
men co-operated well in having their filters changed regularly 
and only one burner was on record as being constantly reprimanded 
for his apathy.
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Section E.II METHODS, ORGANISATION OF THE SURVEY AND RESULTS
1. Methods
The biochemical data for all tests was obtained using the methods 
listed in Section A.II.
2. Organisation of the Survey
From a ship-breaking yard employing 142 people, a total of 48 
were chosen for the survey. A cross-section of all workers on the 
site were selected. Within each particular group, the duration of 
exposure to lead of each individual was as varied as possible. With 
the co-operation of the management, lead-free containers were dis­
tributed to groups of workers the evening before each visit, so that 
overnight urine specimens could be collected. Such samples were 
less likely to be contaminated that those collected during the day. 
When urine samples were collected, blood samples were also taken.
Each employee stated his duration of lead exposure, whether a 
protective mask was worn and for what percentage of his working 
time. Blood samples were analysed for lead and the presence or 
absence of punctate basophilia was noted. Haemoglobin and packed 
cell volume were determined. Urine samples were analysed for lead, 
coproporphyrin and S -aminolaevulic acid. This information is 
listed in Table 10.
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Employees 1-46 worked in a ship-breaking yard on Clydeside. 
Employees 49-55 worked in this or another subsidiary ship-breaking 
yard of the same firm. Employee 56 worked in a metal foundry as 
a lead smelter. Employee 57 was a foreman in a battery factory, 
listed in Part A as Case 8. Nos. 49-57 all attended outpatient
clinics, presenting with various symptoms of subacute or chronic lead
intoxication. The results for nos. 49-57 listed in Table 10 are 
those before treatment was given. Urine results are incomplete 
due to spot samples being small. These latter 9 lead workers with 
symptoms may serve as a basis for comparison with the group of
burners, the majority of whom described symptoms of a milder nature -
constipation, occasional abdominal pain - or none at all.
3. Results
A summary of results is given in Table 10.
a) Working distance from site of lead burning
The distance in yards which each employee in the ship-breaking 
yard worked from the site of lead burning was measured. This 
distance was plotted against blood lead and urinary lead, CP and ALA 
for each worker respectively. The upper normal limits for lead,
CP and ALA, derived from results in Section A. II, are shown in 
Table 11.
Mean + 2 S.D*
Blood lead 59*3
jig./lOO ml.
Urinary lead 48©3
|ig./litre
Urinary CP 181.0
(ig./litre
Urinary ALA 0.36
mg./lOO ml.
TABLE 11
Upper limit (mean + two standard 
deviations) of blood lead and urinary 
lead, coproporphyrin and 6-aminolaevulic 
acid in 20 normal subjects.
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The relationship between blood lead and distance is shown in 
Fig. 20. Blood lead values above normal were recorded for burners
X  *b
(22 out of 24)3 strippers (4 out of 6), slingers (2 total) and 
crane operators (3 total), working 0, 3* 3 and 9 yards respectively 
from the site of lead burning. Those working at 25 and 30 yards
from the lead site had blood lead values about the upper normal limit.
At 50 yards, normal blood lead levels were recorded.
When the urinary lead excretion was plotted against distance, 
values above the upper normal limit were noted for burners (23 out 
of 24), strippers (2 out of 6), slingers (2 total) and crane opera­
tors (3 total), working 0, 3, 3 and 9 yards respectively from the 
site of lead burning. At 25 and 30 yards, 3 out of 9 workers had
abnormal urinary lead excretion.
About half of the values for the urinary excretion of CP by
burners fell within the normal range. All other groups of workers
showed normal levels of CP excretion.
By contrast the urinary excretion of ALA by burners was mostly 
abnormal, only 3 normal values being recorded. All other workers, 
with the exception of one slinger and one crane operator (working
x Strippers strip and separate metal scrap left by burners.
+ Slingers load metal scrap into wagons.
Figure 20. Relationship between blood lead and working 
distance from the site of lead burning for Nos. 1-48.
Figure 21. Relationship between years of exposure to 
lead and the excretion of urinary lead for Nos. 1-24.
The curve is drawn through the mean of five points 
listed in Table 12. The mean urinary lead ± two standard 
deviations in normal subjects is shown.
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3 and 9 yards respectively from the site of lead burning) had levels 
of ALA within the normal range.
b) Duration of exposure to lead (Burners Only)
The number of years that each burner had been actively working 
with lead-containing metals, i.e. his duration of exposure to lead, 
was obtained and related to his excretion of urinary lead;, CP and 
ALA and blood lead respectively.
The duration of lead exposure for the group of 24 burners has 
been divided into five periods as listed in Table 12, and the mean 
value of lead, CP and ALA for each period stated. The following 
paragraph refers to mean values of lead^CP and ALA at all times.
During the first 3 years of lead exposure, there was a sharp 
rise in the excretion of urinary lead (Fig. 2l), a steady rise in 
blood lead and the urinary excretion of ALA, and a gentler rise in 
the excretion of urinary CP. Between 4 and 7 years, the excretion
of urinary CP increased with that of urinary lead while the blood
lead and the excretion of urinary ALA tended to remain constant.
With continued exposure to lead of 8-11 years, the urinary lead 
tended to remain constant, while the blood lead began to rise 
associated with a rise in the excretion of ALA and a fall in the
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excretion of CP. Between 12 and 16 years, the excretion of urinary 
lead began to decline while that of blood lead and urinary CP and 
ALA remained constant. From 17-35 years, the urinary excretion of 
lead, CP and ALA decreased while that of blood lead remained con­
stant. This decrease in the later years was probably due to burners 
being put on to lighter work because of advancing years.
c) Mask Protection (Burners Only)
Since each burner was asked to assess, as a percentage, the 
length of time he wore his mask daily, these figures may well be sub­
ject to large errors.
Inspection of the graphs relating % Mask Protection to urinary 
lead, CP and ALA respectively, showed a very wide scatter of points 
■with a tendency for the excretion of these three substances to 
increase with diminishing mask protection.
Since the majority of blood lead values lie in the 50-100 ^ ig 
range, the average blood lead did not vary with varying mask protec­
tion.
d) Haemoglobin
The relationship of haemoglobin with blood lead and urinary 
lead, CP and ALA respectively was determined by calculating the
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correlation coefficient (Table 13). None was significant but 
it must be remembered that about 50% of the employees showed little 
or no chemical evidence of lead exposure. The correlation between 
haemoglobin and blood lead is shown (Fig. 22). The decrease of 
haemoglobin was associated with an increasing blood lead (and urinary 
lead, CP and ALA respectively).
e) Blood lead. Relationship with urinary lead, CP and ALA.
The correlation between blood lead and urinary lead, CP and ALA 
respectively was not significant (Table 13). This is confirmed 
in part by the studies of Perales & Gonzales (1954) who obtained a 
correlation coefficient for blood and urine lead of + 0.20. Fig.
23 shows the plot of blood lead versus urine lead.
f) Urinary lead. Relationship with urinary CP and ALA.
There was a highly significant correlation between urinary
lead and urinary ALA (Table 13). As the urinary excretion of lead 
increased initially, that of CP and ALA remained within normal 
limits.
At approximately 75 and 100 jig of lead/litre urine, the urinary 
excretion of ALA and CP respectively began to diverge from normal 
values (Figs. 24, 25).
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Figure 22. Correlation between haemoglobin and blood 
lead in 55 workers. The regression line of haemoglobin 
on blood lead is drawn.
Figure 23. Correlation between blood and urinary lead 
in 50 workers. The regression line of blood lea.d on 
urinary lead is drawn.
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Figure 24. Correlation between the urinary excretion 
of lead and cf- aminolaevulic acid in 50 workers. The 
regression line of lead on ALA is drawn.
Figure 25. Correlation between the urinary excretion 
of lead and coproporphyrin in 51 workers. The regression 
line of lead on CP is drawn.
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g) Urinary CP. Relationship -with urinary ALA.
The correlation between urinary CP and urinary ALA was highly 
significant. CP and ALA initially tended to increase together, 
but well beyond the upper normal limits of both, the scatter of 
points became greater, apparently due to the variability of CP 
values (i.e. low CP values with high ALA values).
h) Blood
i) Haemoglobin and packed cell volume (P.C.V.). Anaemia 
is a secondary symptom in lead intoxication. Where the haemo­
globin is low, the P.C.V. should be correspondingly lowered.
Among nos. 1-48* only two subjects, nos. 12 and 21, had 
a haemoglobin of 12 or less. No. 12 had a fairly high blood lead, 
98 jug/100 ml, although his urinary CP and ALA excretion were normal. 
No. 21 had finished an extended course of penicillamine ten weeks 
previously and although his urinary lead, CP and ALA were normal, 
his blood lead was high, 186 p.g/100 ml.
ii) Punctate basophilia. Among nos. 1-48, only No. 21 
showed the presence of stippled cells in peripheral blood. Three 
of the nine outpatients showed basophilic stippling of erythrocytes. 
Nos. 21, 55, 56 and 57 had blood lead levels of 186, 90, 324 and
146 jig/100 ml respectively and haemoglobin values of 11.9* 14-2, 
12.3 and 11.4 g/100 ml respectively.
4- Conclusions
1. The chemical tests for blood lead, urinary lead, CP 
and ALA were shown to be sensitive enough to detect 
industrial lead exposure at its outset.
2. Of 23 potentially lead exposed subjects (excluding 
burners), 14 had lead in blood levels above the 
normal upper limit stated in Table 11. These were:- 
brass burner (l), strippers (4/6), slingers (2/2), 
crane operators (2/2), general labourer and fireman (l) 
and ship manager (l).
3. No relationship was observed between the clinical 
manifestations of lead poisoning and its chemistry, 
e.g. one burner with a blood lead of 306 pg/100 ml 
did not complain of any specific symptoms. His 
haemoglobin was 15.2 g another burner with a
blood lead of 186 jxgJ100 ml and a haemoglobin of
11.9 g % also felt quite well; a battery worker 
with a blood lead of 146 jig/100 ml and a haemoglobin 
of 11.4 g % had wrist drop.
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Section B.III 
Discussion
At one time, the sole screening method used by many industrial 
concerns for the diagnosis of lead exposure was that of the presence 
of stippling of young red cells. This was regarded as an early sign 
of lead poisoning. Such cells however are not peculiar to lead 
absorption. On the other hand, in many cases of undoubted lead 
poisoning and in chronic cases, the presence of basophilic stippling 
is not demonstrable (Waldman & Seideman, 1950). Maloof (1950) has 
stated that not too much emphasis should be placed on the absence 
of stippled cells. As shown in Table 10, the almost total absence 
of stippling gives weight to this view.
Although the determination of lead in blood can give an insight 
into the length and intensity of lead exposure, changes in the 
urinary lead concentration occur more promptly and are more marked 
than those of blood concentration (Kehoe 1935). In 1961 (Lee 3) 
Kehoe stated that the critical level above which lead intoxication 
must be diagnosed, is a little above or a little below BO jig/
100 g whole blood. The lead in urine concentration which corres­
ponds to the critical value of blood is a range rather than a
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single value because of the physiological factors which result in 
an appreciable variability in the rate of the urinary excretion 
of lead. The value may be as low as 150 jig lead/litre or as high 
as 240 )±g lead/litre.
Many workers state that lead in blood values greater than 
50 ^ LLg/lOO ml or 50 jig/lOO g should not be considered normal (Momcilo 
et al, 1955; Bradley et al, 1956 respectively). This is in agree­
ment with the normal values established in Part A of this study 
for blood lead, the highest of which was 49.1 jig/lOO ml. Using 
the normal lead values obtained earlier, the mean + 2 standard 
deviations (39-3 Jig/lOO ml blood, 48.3 fig/litre urine) however has 
been taken arbitrarily as the limit above which lead exposure was 
diagnosed in this study. The following paragraphs are based on 
this assumption. No dividing line was drawn between lead exposure 
and lead intoxication.
A falling haemoglobin associated with a rising blood lead 
appeared at the later stages of lead exposure, i.e. when a haemo­
globin level of 12$ or less was detected, this appeared to be 
associated with a fairly lengthy exposure to lead since high lead in 
blood levels ( J  100 jig/lOO ml) were also present.
"When results of the tests for subjects 1-48 were examined, 
the greatest degree of lead exposure was experienced by burners 
(Group l), followed by crane operators and slingers (Group 2). 
Strippers (Group 3) were the next most exposed, followed by all 
others working 25-30 yards from the site of burning (Group 4)- 
It is of interest to note in Group 2 that because the crane 
operators worked almost directly above the site of lead burning, 
they ran the same risk of exposure to lead as slingers who 
worked much closer to the site of lead burning.
Among the 24 burners in Group 1, 21 excreted abnormal 
amounts of urinary lead and ALA. 18 of the 21 had abnormal 
blood lead levels, but only 14 of the 21 showed abnormal ex­
cretion of CP. On the other hand, the excretion of abnormal 
quantities of CP was always associated with an abnormal urinary 
lead and ALA and (except for one case) with an abnormal blood 
lead. In Group 2, all four subjects showed abnormal lead in 
blood and lead in urine values. Only one ALA value was 
abnormal. All CP levels were normal. In Groups 3 and l±} 
the excretion of CP and ALA was normal, although many had 
abnormal urine and/or blood lead values.
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The above evidence suggested that the excretion of CP
attained abnormal levels after that of ALA, rather than both 
oJo
attainingAnormal values together. Haeger Aronsen (i960 p. 102) 
has also suggested this. Assuming this to be the case, the 
development of lead exposure in the majority of subjects follows 
the general pattern of an increase, above the normal limit, of 
l) urinary lead 2) blood lead 3) urinary ALA and 4) urinary 
CP.
Stages 3 and k3 representing the biochemical change in the 
enzyme system for the porphyrins, may be regarded as one of the 
earliest biological changes produced by lead (de Langen and 
ten Berg, 1948; Maloof, 1950). Following the increased excretion 
of CP, basophilic stippled cells may appear (de Langen and ten Berg, 
1948) later confirmed by Maloof (1950). As the exposure becomes 
greater lead anaemia is likely to be detected (p. 73) and this 
may be followed by the various symptoms of lead poisoning including 
colic and palsy. Maloof (1950) stated that the excretion of 
CP was greatly in excess of normal long before any symptoms 
appeared.
For routine screening of workers and.early diagnosis of 
lead exposure, the determination of urinary ALA and CP would be
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of value, especially since it has been established that the 
latter two are related in a highly significant manner to that 
of urinary lead (Table 13)- As yet no simple semi-quantitative 
test is known for the determination of ALA. in urine but one 
is available for CP (Waldman & Seideman, 1950; Harrold et al* 
1952). This test is based on the fact that porphyrins are 
pigments which fluoresce in UV light. If a small aliquot of
acidified urine is shaken with ether, the presence or absence 
of porphyrins, extracted into the ether layer, can be seen 
under UV light. A positive test, which may be graded into at 
least 3 categories occurs when the lead in urine value is 
greater than 150 p.g lead per litre (Waldman & Seideman, 1950; 
Harrold et al, 1952).
Of the 4 main tests reviewed i.e. blood lead, urinary 
lead CP and ALA, al1 are sensitive indices of lead exposure.
Only that of CP however has been adopted, in simplified form, 
as a rapid screening method for the detection of industrial 
lead exposure, and it is recognised as the most simple and most 
useful indication of the degree of exposure to lead (Horiuchi,
1955).
Routine screening should be extended to subjects working 
within a 10 yard range of the perimeter of the site of lead 
burning, since they are likely to be exposed to lead fumes and 
airborne particles.
In agreement with the findings of Perales et al (1954), 
there was no significant correlation between the symptoms of 
lead poisoning and the levels of blood lead and urinary lead, 
coproporphyrin and 8 aminolaevulic acid respectively. It 
appears that the tolerance level of absorped lead varies from 
person to person.
Summary
A survey was carried out in a ship-breaking yard to 
determine the sensitivity of the following tests - blood lead, 
urinary lead, coproporphyrin and <S -aminolaevulic acid - as 
screening methods in the detection of lead exposure. The 
urinary excretions of coproporphyrin and 8 -aminolaevulic acid 
respectively have been shown to be related to the urinary 
excretion of lead in a highly significant manner (p<0.00l).
The excretion of abnormal quantities of coproporphyrin appeared 
to follow that of 8 -aminolaevulic acid. Since there is as
yet no simplified test for 8 -aminolaevulic acid, that of 
coproporphyrin (available in simplified form) is recommended 
for screening. Basophilic stippling of red cells occurred 
only in a minority of cases. Subjects working within a 10
yard range of the perimeter of the site of lead burning 
should be routinely screened. There was no significant 
correlation between the symptoms of lead poisoning and blood 
lead, urinary lead, coproporphyrin and S -aminolaevulic acid 
respectively.
PART C 0 TER URINARY EXCRETION OP IRON 
IN iiEALTH AND DISEASE.
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Section C.I INTRODUCTION
1. Outline of iron metabolism
In contrast to lead, iron is an essential element of the body* 
The normal adult body contains 3 - 5 g* of iron which is almost 
exclusively complexed to protein (eg. transferrin, ferritin) or 
present in haem (eg. haemoglobin, myoglobin, haem enzymes).
About 66$ of the total iron is present in circulating haemoglobin. 
Approximately 25$ is present as reserve iron, stored mainly in 
liver, spleen, kidney and bone marrow in the form of ferritin 
and haemosiderin. Ifyoglobin contains about 3$ of the total iron 
and about 5$ is accounted for in the parenchyma of other organs.
The remaining 1$ is distributed among the various haem-containing 
enzymes and -transferrin (Moore, 1958)*
Ingested iron must be reduced to the ferrous form in stomach 
and intestine before it can be absorbed (Moore et al., 1944)* 
Although small amounts of iron may be absorbed by the stomach, the 
absorption of iron is greatest in the upper part of the small 
intestine and progressively less in the more distal segments 
(Wintrobe, 1956). The diminishing absorption of iron from the 
jejunum and ileum may well be a result of the gradual conversion 
of iron to less soluble complexes on its passage down the 
gastrointestinal tract (Fig. 26).
It has been found that patients with iron deficiency absorb 
iron more efficiently than do normal subjects (Hahn et al., 1959? 
Dubach et al., 1948) that ferritin is synthesised in the
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intestinal mucosa of guinea-pigs as a direct result of the 
administration of large quantities of iron (Granick, 1946a)*
There is no doubt that the intestinal mucosa serves to some 
extent as a regulator of iron excretion and that the presence or 
absence of ferritin appears to be of some importance in this 
process (Crosby, 1963) as discussed in Part D. There is also 
evidence that the absorption of iron may be increased when 
erythropoiesis is stimulated (Bothwell et al., 1956)#
When iron passes into the plasma, it is oxidised to the 
ferric state and transported by transferrin, a ^  globulin. 
Although the amount of iron in plasma is small - about 50 - 
180 |ig.% - its turnover is rapid, averaging approximately 
560 fig• per kg. of body weight per day (Bush et al., 1956). This 
quantity of plasma iron in a man weighing JO kg. is roughly 
35 - 40 mg. per day and of this, 20 - 25 mg. are used by the bone 
marrow each day for haemoglobin synthesis (Moore, 1958)* A. small 
amount is taken up by other cells of the body for the formation 
of myoglobin and of cellular enzymes. Iron transported in the 
plasma can be deposited in the storage organs where it may be 
used or excreted. The quantity of iron stores in the tissues of 
a healthy adult is approximately 1 g., the liver and spleen being 
the chief storage sites. Storage iron is found intracellularly 
in a protein complex as ferritin (which is water soluble) and as 
haemosiderin (which is water insoluble) (Shoden et al., 1953)® 
Both compounds are capable of being mobilised by the body for
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haemoglobin synthesis when the need arises.
One very important characteristic of iron metabolism is the 
efficient way the body conserves the metal. When erythrocytes are 
destroyed, almost all of the iron released from haemoglobin is 
reused. Iron released from other cells that die is similarly 
conserved. Small but significant amounts are excreted. Whenever 
erythrocytes are lost by haemorrhage or in urine or whenever cells 
are desquamated from the surfaces of the body or from body orifices, 
the iron they contain must be considered lost.
Whenever iron loss exceeds iron absorption, the blood 
haemoglobin falls and anaemia develops. In both sideropenia and 
iron deficiency anaemia, there is an absence of stainable iron 
in the bone marrow and in both states, the serum iron is decreased 
(normal mean + 2 S.D. is 134 + 51 Dreyfus and Shapira, 1964)
while the total serum iron binding capacity is increased (normal 
range 300 - 350 (ig.^ * Dreyfus and Shapira, 1964)#
The only important use of iron in modem medicine is in the 
treatment of iron deficiency anaemia. The administration of iron to 
patients with normal blood values serves only to increase the 
reserve iron of the body and not to increase the red blood cells or 
haemoglobin above their normal physiological limits. On the other 
hand, a large increase in the reserve iron of the body over a period 
of years, may be brought about by a defect in metabolism. Such is 
the case in primary idiopathic haemochromatosis where the process 
of accumulation of iron within the body is so slow that a great number
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of years may pass before the disease is detected. This disease is
now regarded as a congenital one and it must be assumed that the
onset of accumulation of iron dates back to childhood. Over such a 
lengthy period, the daily accumulation of small quantities of iron 
may be due to the plasma-storage iron exchange (which is normally 
very small) becoming the major component of plasma iron turnover.
Iron excess in the body results in the deposition of iron in
the parenchyma of many organ systems, as in idiopathic
haemochromatosis, and may lead to eventual tissue damage, manifested 
by altered organ function and fibrosis. This tends to increase with 
the passage of time. Appreciation of this problem has led to 
therapeutic efforts to remove iron from the body in an attempt 
to arrest or reverse the course of these iron storage diseases. 
Repeated phlebotomy has been demonstrated to be the best effective 
method of iron removal, and is now accepted as the treatment of 
choice in cases of idiopathic haemochromatosis. However, in 
patients with haemochromatosis following repeated transfusions for 
various types of refractory anaemia, venesection is not feasible.
In focal iron overload eg. idiopathic pulmonary haemosiderosis, 
excess iron can only be removed by the action of chelating agents,
2, Chelating agents
The most recently introduced chelating agent for iron is 
desferrioxamine B methane sulphonate (desferrioxamine B mesylate).
The Ciba trade name for this substance is Desferal. The ferrioxamines 
are members of a class of naturally occurring substances, the so- 
called siderochromes. These combine with ferric iron to form
brownish-red complexes and they can be divided into two groups, 
the sideromycins and The sideramines. The sideromycins are iron- 
containing antibiotics. Sideramines are substances which on the 
one hand promote the growth of certain micro-organisms and on the 
other may antagonise the antibacterial effects of the sideromycins.
Ferrioxamine B which contains one molecule of chelated ferric 
iron, belongs to the sideramines and is isolated as a metabolite 
from Streptomyces pilosus. Ferrioxamine B was first used in the 
treatment of anaemia associated with iron deficiency but trials 
were not successful due to the compound being excreted rapidly 
by the kidney without significant release of iron. The use of the 
corresponding iron-free compound, desferrioxamine B, as an iron 
chelator in vivo was then investigated. Desferrioxamine B, a 
trihyroxamic acid derivative forms an octahedral complex with 
ferric iron called ferrioxamine B (Fig. 27). oince the complex 
has a low molecular weight and hydrophilic properties, it is 
easily excreted by the kidney. When given orally, Desferal is 
poorly absorbed from the small intestine. After parenteral 
administration in animals, it is widely distributed in the 
tissues. The mobilisation of tissue iron is indicated by a rise in 
serum iron due to the presence of the complex. Clinical trials have 
confirmed that Desferal is well tolerated and non-toxic. No side 
reactions have been described. Of great importance is the fact 
that Desferal is a selective chelator of iron. Althougn the 
stability constant of ferrioxamine is 10^ (Bickel et al., i960),
(CH2)5NH2
CO 1 NH
I /  \  1
(CH2)2 Cv q- /(CH2)
y / C o — n
I /Fe3\  | |
/0- ° = c
(CH2)5-N  N(CH2)
I c* •
NH V CO
CH3
Figure ?7. Ferrioxamine B.
Desferal has a minimal effect on the urinary excretion of sodium, 
potassium, zinc, cobalt, cadmium, copper, magnesium, aluminium, 
manganese and chromium (Tripod and Keberle, 1962; Bickel et al., I960,
1962).
Desferal can chelate ionic iron and ferritin iron (Wohler,
1964b) but it cannot chelate iron bound to transferrin, or 
haemoglobin iron in washed or haemolysed erythrocytes (Moeschlin 
and Schnider, 1963). There is conflicting evidence as to whether 
it can remove iron from haemosiderin (Mann and Maier, 1962; Wohler, 
1964b).
Before the advent of Desferal, two other chelating agents were 
used to complex iron in patients with iron storage disease. These 
were calcium disodium ethylenediaminetetraacetate (E.D.T.A.) and 
calcium trisodium diethylenetriaminepentaacetate (B.T.P.A). Brick 
and Rath (1964) found that dose for dose, the administration of 
D.T.P.A. caused a far greater excretion of iron than that obtained 
with E.D.T.A. However, these versenate derivatives enhance the 
excretion of essential trace elements like copper, zinc and magnesium 
(Moeschlin and Schnider, 1964)* It is of interest that although at 
pH 7*25 the Fe(lll) - Desferal complex is more stable than the 
corresponding E.D.T.A. and D.T.P.A. complexes, the position is 
reversed at pH 4 (Schubert, 1964).
About 1962, small quantities of Desferal, made available for 
research purposes, stimulated interest in the urinary excretion 
of iron (Bannerman et al., 1962; Smith, 1962; Wohler, 1964«>)»
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Under normal conditions, the loss of iron in the urine is apparently 
insignificant (Lintzel, 1931)• In ten normal male subjects,
Cartwright et al,, (1954) found the mean urinary iron excretion to be 
48 |ig,/24 hours; in no instance was a value higher than 64 |-ig./24 
hours obtained. This view was confirmed by the radio-isotopic studies 
of Dubach et al., (1955) which showed negligible amounts of radio­
activity in the urine in the first two days following intravenous 
injection of radio-iron.
It has already been shown that the administration of Desferal 
is useful in the detection of states of generalised iron overload 
(Bannerman et al., 1962). In such states, Desferal greatly 
increased the urinary excretion of iron. If, in patients with iron 
deficiency and iron overload, and in normal subjects, a correlation 
could be established between the body iron stores and the urinary 
output of iron during Desferal treatment, then such a test would be 
of use as a diagnostic aid. In states of iron deficiency especially, 
such a test could provide a measure of tissue iron depletion and hence 
avoid the necessity of marrow aspiration.
3* Purpose of the study
The first part of the study deals with the effect of Desferal 
on the urinary iron excretion of normal subjects and of patients 
with sideropenia and iron deficiency anaemia. Studies with Desferal 
were carried out in diseases with focal iron overload (eg. the 
renal haemosiderosis associated with paroxysmal nocturnal 
haemoglobinuria and idiopathic pulmonary haemosiderosis) and in
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states of generalised iron overload (idiopathic haemochromatosis).
In 1954, Cartwright and his co-workers demonstrated that 
increased urinary excretion of iron took place in patients with gross 
proteinuria. Further studies to determine the mechanism of this 
excretion were carried out and are described in the second part of 
this study.
In 1965t Fielding noted that the urinary excretion of iron in
patients with a haemolytic condition was somewhat greater than in
healthy controls. In the same year, in collaboration with Dr.A.
Goldberg, Keberle carried out experiments on two guinea-pigs,
administering oral phenylhydrazine to induce haemolysis. Both
59animals were given Fe as ferrous sulphate by gastric tube on 
Day 1 and on Day 14. On Day 40, guinea-pig A was given 
phenylhydrazine (30 mg./kg.) daily for four days, as well as 
Desferal (100 mg./kg.) daily for five days. Control guinea-pig 
B was given only ifesferal for five days. The radioactivity of
59Fe, excreted in urine and faeces,was determined daily during
this period in A and B and is shown in Fig. 28. On Day 41> the
59urinary excretion of Fe in A rose immediately in response to the 
combined Desferal and phenylhydrazine therapy, showing a maximum 
eightfold rise over control B on Day 44* The excretion of faecal
59Fe in A however, did not rise significantly until Day 44 (ie. the 
fourth day of combined treatment) when a fourfold increase over 
control B was recorded. In an earlier experiment, using the same 
animals and same doses, a single dose of phenylhydrazine had been 
given during a course of Desferal treatment. Only a slight increase 
in the elimination of urinary and faecal ^Fe, over the control,
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was found*
From the above experiments, it can be seen that the faecal and 
urinary excretion of iron during Desferal treatment was only 
significantly increased when phenylhydrazine was given for more 
than one day. The advantages and disadvantages of administering 
phenylhydrazine in combination with Desferal to patients with iron 
overload were considered*
In primary idiopathic haemochromatosis, long term treatment 
with Desferal has been of iimited value since it generally removes 
no more than 20 mg. of iron per day (Moeschlin and Schnider, 1963)* 
Since phlebotomy is the treatment of choice for primary idiopathic 
haemochromatosis, this figure compares unfavourably with the 
venesection of one pint of blood which effectively removes 
approximately 230 mg. of iron. If, in patients with primary idiopathic 
haemochromatosis, the excretion of iron during combined phenylhydrazine 
and Desferal treatment was enhanced to over 200 mg. of iron per week, 
then this treatment could serve as an alternative to that of 
phlebotomy. However, because phenylhydrazine is such an effective 
haemolytic agent when introduced into the body, careful consideration 
was given to the dose administered. Phenylhydrazine has been little 
used medicinally in the past forty years except in the treatment of 
patients with polycythaemia where daily doses of 100 mg. have been 
extensively employed without any untoward effect (Wintrobe, 1961).
The third part of the study deals with the effect of the 
haemolysis provoked by varying doses of phenylhydrazine on the 
urinary iron excretion during Desferal treatment in patients with 
▼arious forms of iron overload.
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Section G.II METHODS AND RESULTS
1, Iron estimation
2:2^ dipyridyl and 1:10 phenanthroline are sensitive reagents 
for the quantitative colorimetric determination of traces of iron, 
giving red and orange-red complexes respectively with ferrous iron 
in aqueous solution. Three molecules of each bidentate ligand 
react with one molecule of ferrous iron respectively to give 
coordination complexes in which the arrangement of nitrogen atoms 
around the iron molecule is octahedral«
2:2 dipyridyl
X+
1*10 phenanthroline
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2:2^ dipyridyl and o-phenanthroline can complex ferrous iron 
in acid or alkaline solution. In biological materials, however, 
ferrous iron is best complexed under acidic conditions to avoid the 
precipitation of hydroxides and phosphates of interfering metals.
The concentration of iron in urine was determined initially using 
the o-phenanthroline method and latterly using the dipyridyl method.
Concentration and digestion of 100 ml. urine samples were carried 
out as before (Section A.II). On addition of 2 ml. of deionised 
water to the urine digest contained in 2 ml. of 36N sulphuric 
acid, calcium sulphate was precipitated. Although calcium sulphate 
dissolves in a saturated solution of ammonium sulphate by forming the 
double salt CaSO^ (NH^^SO^. HgO, the solution obtained after pH 
adjustment was not perfectly clear. Rather than buffer the existing 
salt to make it completely soluble, it was decided to eliminate 
calcium sulphate by filtration. On filtration, loss of iron, 
through precipitation with calcium sulphate, was avoided by the 
addition of 2 ml. hydrochloric acid to the digest to convert iron 
present as ferric sulphate to the more stable chloride compound.
The yellow colour of ferric chloride in solution was only visible 
when 40 fig. or more of iron were present. The digest was filtered 
into a volumetric flask, using washed No. 44 (7cnu) filter paper, and 
the Kjeldahl flask rinsed out with 5 * 6  small portions of water.
After trials with various methods of pH adjustment and colour 
development, using hydroquinone as reducing agent and o-phenanthroline 
as complexing agent, there was still inadequate duplication of results. 
It was not known whether the method for colour development was
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inadequate or whether iron had been lost during digestion and/or
during filtration. The possible loss of iron during digestion and
59during transfer to the volumetric flask was determined using Fe.
One ml. of a solution of radioactive ferric chloride was added
to two 100 ml. urine samples from a normal subject and to a Kjeldahl
flask (for the reagent blank) in the following manners- The
59activity of 1 ml. of Fe solution contained in a test-tube was
determined using a scintillation counter. The radioactive solution
59was pioured into a 100 ml. urine aliquot and the activity of the Fe 
remaining in the test-tube determined. The difference in activity 
was that added to the urine sample. The urine samples were 
concentrated and digested as before. 2 ml. of water and 2 ml. 5JJ 
hydrochloric acid were added to the digest. This was heated gently 
for 2 - 3  minutes to eliminate the last traces of nitric acid.
(When less than 40 (ig. of iron were present (ie. no yellow colour 
due to ferric chloride) traces of nitric acid in hydrochloric acid 
were visible as the yellow colour of aqua regia. On gentle heating 
and swirling, nitric acid was evolved and the solution became 
colourless). The digest was allowed to stand overnight to allow 
complete precipitation of calcium sulphate and filtered into a 25 ml. 
volumetric flask. The pH was adjusted and hydroquinone and o-phenan­
throline were added. After making up to volume, the activity was
determined and correction made for decay*
59The recovery of Fe from urine as shown in Table 14 was good 
but the colorimetric determination of iron, estimated at the same 
time was not, thus providing that the method of colour development 
required modification*
Sample ^Fe added ^Fe found $ "^ Fe
c.p.m. c. p. m. recovered
100 ml. urine 3049 2923 96
100 ml. urine 3316 3283 99
Blank 3078 2879 94
TABLE 14
59Recovery of Fe added to 100 ml. aliquots of urine.
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Optimal pH
o-phenanthroline was used to complex ferrous iron at 
pH 2 - 4.5 (Possible range 2 - 9 ) *  In this pH range, the 
precipitation of hydroxides and phosphates of interfering metals are 
prevented. At pH 5> copper may interfere due to the reducxion of 
Cu(ll) to Cu(l) which forms a coloured complex with o-phenanthroline 
(Sandell, 1959 P* 559)* Since the concentration of iron in normal 
urine was likely to be in the range 2 - 1 0  pg.% (Cartwright et al.,
1954)> it was not feasible to divide the filtrate into two parts 
and use 1 part to determine the pH adjustment required.
The pH was initially adjusted to pH 4*5 hy the addition of 8 ml. 
of 6M ammonium acetate for every 1 ml. of sulphuric acid (l^SO^) 
used in the digestion process. When 2 ml of was used (the
minimum volume required for the digestion of 100 ml. of urine) 
ammonium acetate had to be used to wash out the kjeldahl flask 
during transfer of the digest to the 25 ml volumetric flask. Such 
an alkaline wash may cause the remaining traces of iron in the 
Kjeldahl flask to be precipitated as ferric phosphaxe (Although 
phosphate is destroyed by ^SO^ digestion, pyrophosphate may be 
formed. On the addition of water, this is converxed to phosphate).
Due to some ^eing used up in salt formation during digestion,
the volume of 6M ammonium acetate added may be in excess giving pH 
values above 5* Ihe use of ammonium acetate was discontinued.
p-nitrophenol was the only suitable indicator for the adjustment 
of pH since it is colourless in acid solution and yellow in alkaline 
solution, the yellow end-point being visible at pH 5*6. It was intended 
to add ammonium hydroxide to the iron-containing filtrate until the
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yellow end-poini, of p-nitrophenol was reached and, by the addition 
Of a slight excess of acid, ensure a colourless solution and a pH 
below 5* The excess acid was added as rather than as
hydrochloric acid since this may intensify the yellow colour of 
ferric chloride, when iron is present in large quantities.
Two drops of Vfo w/v p-nitrophenol in lOfo v/v ethyl alcohol were 
added to the iron-containing filtrate in a 20 ml. volumetric flask. 
Using I4N ammonium hydroxide, the pH was adjusted to the yellow 
end-point, precipitation of insoluble hydroxides occurring only in 
a few instances. 1 - 5  small drops of ^N.I^SO^ were added until 
the yellow colour just disappeared and no cloudiness was observed.
At this stage, the pH of the majority of samples was 5*0 - 5*5®
Above pH 4, there was a tendency for traces of insoluble material to 
remain. While the solution was still warm (about 40°C) with the heat 
of neutralisation of ^SO^, 1*5 ml. 2$ w/v aqueous hydroquinone and 
0.5 ml. 1:10 phenanthroline hydrate (2fo w/v alcoholic solution) 
were added. The solution was allowed to stand for 2 hours for complete 
colour development (Bandemar and Schaible, 1944) and made up to 
volume. The optical density of the solution was read at 508 mji 
on the Hilger uvispek. Estimations were carried out in duplicate.
It was found that the reducing agent and complexing agent had 
to be added to a warm iron solution otherwise full colour development 
did not occur within two hours. At higher concentrations than given 
above, hydroquinone tended to precipitate out of solution on standing 
for two hours. Hydroquinone was made up daily.
The absorption maximum of the ferrous-phananthroline complex An 
aqueous solution was found to be 507 • 508 m(i. on the Hilger uvispek
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(Pig.29)« This is in agreement with the findings of Sandell (1959> 
p. 525)o
A stock solution of iron (0.1 mg./ml.) was prepared by- 
dissolving 863 mg. of analar ferric ammonium sulphate 
FeNH^(SO^. 121^0 in ion-free water containing 10 ml of U N  
hydrochloric acid and making up to 1 litre. The optical density 
of 20 ml. solutions of the ferrous-phenanthroline complex for 
concentrations of iron up to 100 (ig. were determined. The 
calibration graph was linear, obeying Beer*s Law. The tangent 
was 0.01018o
An alternative method for estimating iron using sodium sulphite 
Na^SO^.TH^O as reducing agent and 2:2^ dipyridyl as complexing 
agent was also developed.
Solutions of sodium sulphite are alkaline. 2*2^ dipyridyl 
is insoluble in water and is best dissolved in glacial acetic acid 
before dilution with water. Initial experiments with varying 
concentrations of sodium sulphite and 2:2^ dipyridyl were made 
difficult due to pH requirements of the iron complex (so that copper 
did not interfere) and due to the maximum allowable volume of iron 
reagents in the 20 ml. volumetric flask being about 2-g- - 3 nil.
1 ml. of 2$ (w/v) 2:2^ dipyridyl in 60$ v/v acetic acid and 1 ml. 
of O.75M sodium sulphite were added to an iron-containing solution 
(prepared as before) at pH 3*0 - 3*3* (Addition of sulphite before 
dipyridyl should be avoided since this causes the pH to rise to 
about 9 and brings about heavy precipitation). An aliquot of the 
solution in a graduated test-tube was placed in a waterbath at 100°C
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for 15 minutes to attain full colour development. After cooling and 
making up to volume, the optical density of the solution was read 
at 522 mfi. (The absorption maximum of a solution of the ferrous- 
dipyridyl complex was found to be 522 mfi. on the Hilger uvispek 
(Fig. 23), confirming the findings of Sandell (1959> P* 525)). A 
calibration graph was drawn of the optical density of 20 ml. solutions 
of the ferrous-dipyridyl complex at varying concentrations of iron 
up to 100 fig . The calibration graph was linear. The tangent was 
0.008.
The estimation of iron in urine using both methods gave the same 
results. More attention to detail was required for the o-phenanthroline 
method: firstly, the iron reagents had to be added to a warm solution, 
otherwise complete colour development did not occur within two hours; 
secondly, care had to be taken that no traces of ammonium hydroxide 
remained in the neck of the volumetric flask, otherwise on the 
addition of hydroquinone, oxidation to brown quinone occurred.
2. Precision of the method of iron estimation
Using the o-phenanthroline method, T,he iron content of six 
100 ml. aliquots of urine from a single patient was estimated. The 
results were 11*5> 11.6, 10.9» 11.0, 10.9 and 10.9 fig* of iron per 
100 ml. urine, mean 11.1, standard deviation + 0.26. The standard 
error calculated from double determinations on 100 urine samples with 
iron concentrations between 1.5 ana 27*0 fig. per 100 ml. of urine 
(mean 17.2 fig.) was 0.4 fig* per 100 ml.
Using the o-phenanthroline and dipyridyl methods, the recovery
95
of known quantities of iron added to aliquots of urine were 
determined. 92 - 112% of the iron added was recovered. (Table 15) •
3# Spot test for iron
A rough quantitative test was developed to determine the presence 
of large quantities of iron in urine, ie. 0.1 to 2.0 mg. per 100 ml.
To four ml. of urine in a test-tube, were added 0.5 ml* 2% w/v 
2s2^  dipyridyl in 60% v/v acetic acid and 0.5 nil. thioglycollic 
acid. After heating for a few minutes in a beaker of water at 
100°C, the colour developed was compared with a series of standard 
iron solutions, of concentration 0.1 to 2.0 mg. per 100 ml. prepared 
in exactly the same manner. The colour of the ferrous-dipyridyl 
complex developed in the comparison standards is stable indefinitely.
Thioglycollic acid is a much stronger reducing agent than 
sodium sulphite, which does not reduce ferric iron under the conditions 
of the test. Although thioglycollic acid itself may react with iron 
in alkaline solution to give a red coloured complex, under the acidic 
conditions of the spot test it acts only as a reducing agent.
This test has only been used to facilitate the selection of an 
iron in urine concentration within the range of determination of the 
methods previously described. The spot test, performed on fifty 
urine samples with iron concentrations from 0.1 to 1.8 mg./lOO ml., 
gave the following results; in 35»14 and 5 tests, the iron concentre 
ation lay within 10, 20 and 30% respectively of the true concentration. 
4* Iron-free glassware
Glassware was freed from iron by immersing in 6N hydrochloric 
acid overnight and rinsing thoroughly with deionised water.
1*10 phenanthroline
Urine IRON ( f i g . )
Aliquot Present Added Pound Recovered
100 ml. 7.3 10 16.5 9.2
7.3 10 18.3 11.0
7.3 20 27.5 20.2
7.3 20 27.8 20.5
100 ml. 34.1 10 44.7 10.6
34.1 10 44.2 10.1
34.1 20 54.9 20.8
34.1 20 54.9 20.8
20 ml. 53,2 10 62.7 9.5
53.2 10 63.0 9.8
53.2 20 72.2 19.0
53.2 20 73.0 19.8
2*2* dipyridyl
25 ml. 41.8 10 51.8 10.0
41.8 10 53.0 11.2
41.8 20 61.1 19.3
41.8 20 63.0 21.2
TABLE 15
Recovery of iron added to various urine aliquots, 
using the 1*10 phenanthroline and 2*2* dipyridyl 
methods.
Polythene winchesters, for urine collection, were freed from iron in 
the same manner.
5. Urinary haemoglobin, ferritin and haemosiderin
The urinary output of iron as haemoglobin, ferritin and 
haemosiderin was estimated in two patients with paroxysmal nocturnal 
haemoglobinuria. The urinary pH was adjusted to 7 with disodium 
hydrogen orthophosphate, and an equal volume of saturated (iron- 
free) ammonium sulphate added. After 2 hours at 0°C, the urine was 
centrifuged; an iron estimation on the supemate represented iron 
in haemoglobin. The precipitate was then extracted with water to 
dissolve ferritin; iron estimations on the supemate and precipitate 
measured iron in ferritin and iron in haemosiderin respectively 
(Drysdale and Kamsay, 1965).
6. Urinary protein
Urinary protein was estimated by the method of Lowry et al.,
(1951) using Folin and Ciocalteau reagent. To 1 ml. of protein 
solution was added 5 nil. of the following solution, prepared freshly 
each day ( 1 ml. 1% w/v copper sulphate + 1 ml. 2% w/v sodium tartrate 
+ 100 ml 2% w/v sodium carbonate in 0.1N sodium hydroxide). After 10 
minutes, 0.5 ml. of 50% v/v Polin and Ciocalteau reagent was added 
and mixed immediately. A blank sample containing 1 ml. water was 
"created in the same manner. Thirty minutes later, the optical density 
of the blue protein complex was read on the Hilger uvispek at 
wavelength 750 mfi. and slit width U.05 mm.
Using standard solutions of crystalline bovine albumin, a 
calibration graph was drawn of optical density versus protein content
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(Fig. 30). Urine aliquots were diluted 10- to 50-fold (to 
give a protein content of 20 mg.$ or less) and two 1 ml. volumes 
taken for duplicate protein estimation. All samples were read 
against a reagent blank. Protein standards were included in each 
batch determination.
Electrophoresis of urinary proteins.
A short length of 2^2" visking tubing containing 25 - 35 nil* 
of urine was placed in a 6" x 1" test-tube containing polyethylene 
glycol, molecular weight 20,000. After concentration to 5 - 10 ml., 
the dialysis tube containing the urine sample was suspended in normal 
saline for a few hours to dialyse out phosphates and other salts.
The urine concentrate was then ready for electrophoresis.
In patients with proteinuria, concentrated dialysed specimens 
of urine can be separated into four fractions - albumin and c<.^  
and p globulins - by electrophoresis in barbitone acetate buffer at 
pH 8.6 (ie. sodium barbitone 20 g., sodium acetate 13 g. > 135*6 ml. 
OolN hydrochloric acid plus water to give a final volume of 2 litres). 
Six 34 cm. strips of Whatman No. 3 chromatography paper 5 cm. broad 
were immersed in buffer, blotted firmly and placed in position in 
the E.E.L. horizontal electrophoresis tank. Two small volumes of 
prepared urine (usually 0.05 and 0.10 ml.) were carefully applied 
in a thin band on a pencil line drawn 13 cm. from the end of each 
strip. The tank was connected to a Volkam power pack and a 
constant current of 2 ma. per strip passed for approximately 24 hours. 
The strips were removed, dried and placed in an air oven at 105°C 
for 15 minutes to denature the protein bands. The protein bands
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Figure 30® Calibration graph of crystalline bovine 
albunin versus optical density at 750 mji on the 
Hilger uvispek.
were stained and fixed by immersing the strips for 5 minutes in a
solution of 1$ w/v bromophenol blue in 95$ alcohol saturated with
mercuric chloride. The Dackground dye was washed away under
running water until a white background was obtained. The strips
were allowed to dry, placed in an oven at 100°C for 5 minutes and
rendered transparent by immersing in liquid paraffin at 110°C
for 30 minutes. Each strip was mounted between glass and placed in
the E.E.L. Scanner. The areas under the peaks of the resulting
scan were proportional xo the relative amounts of the protein
fractions present. (The scan was drawn on 1 inch graph paper to
facilitate the determination of the areas under each peak)* When
the total protein content is known, all protein fractions separated
by electrophoresis can be assigned absolute values,
7* Haematological methods. Serum iron and 
total iron binding capacity,
Haematological measurements were carried out by standard 
techniques (Dacie and Lewis, 1963),
Serum iron and total iron binding capacity were estimated by 
the modified method of Ramsay (1957a, b). Serum iron was determined 
by the sulphite-dipyridyl method. The total iron binding capacity 
was determined by saturation of the iron binding capcixy with a 
calculated excess of iron and removal of the excess unbound iron with 
magnesium carbonate before estimating the iron content of the 
supemate as above.
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8* The effect of Desferal on the urinary excretion 
of iron in normal sub.jects and in patients with 
sideropenia, iron deficiency anaemia and 
iron overload.
Clinical data
The haematologically normal subjects had haemoglobin levels 
of 14* 6 g./lOO ml. or above, a normal percentage saturation of 
the total iron binding capacity and normal amounts of stainable 
iron in the bone marrow. The subjects described as sideropenic 
had haemoglobin values between 12 and 13 g./lOO ml., a percentage 
saturation of the total iron binding capacity below 15$ and an absence 
of stainable iron in bone marrow sections. The patients with iron 
deficiency anaemia had haemoglobin levels below 12.0 g./100 ml., an 
absence of stainable marrow iron, and a saturation of the total iron 
binding capacity below 10$. The iron-deficient subjects had a 
complete response in haemoglobin solely to iron therapy.
The two patients with paroxysmal nocturnal haemoglobinuria had 
a chronic haemolytic anaemia associated with haemoglobinuria and 
haemosiderinuria. Both had hypochromia of the red cells associated 
with an absence of stainable iron in the bone marrow.
One patient with idiopathic pulmonary haemosiderosis was 
studied. He was a young man of 22 years with recurrent severe 
iron deficiency anaemia. The diagnosis was confirmed by chest x-ray 
and lung biopsy which showed macrophages heavily laden with iron.
Desferal test
Twenty-four hour collections of urine were made in iron-free 
polythene containers to provide a basal value for urinary iron output. 
600 mg. of Desferal was then injected intramuscularly and the urine
again collected during the following 24 hours. (This urine 
collection has been called that "during Desferal administration" in 
the Kesults section). A third 24 hour urine collection (called that 
"after Desferal administration") was made in most patients. The 
urinary iron excretion was determined in all instances*
Since a standard dose of desferrioxamine was given to all 
subjects, it was considered important in the sideropenic and iron 
deficiency anaemia patients to relate the subsequent urinary iron 
output to body weight. This is not necessary in patients with iron 
overload since there are large differences between these cases and 
normal subjects. The results in the iron deficient subjects were 
expressed as qg. urinary iron in 24 hour per kg. of lean body mass
and also of whole body weight. A better separation of results was
obtained between the two iron deficient groups and the normal group 
when lean body mass rather than whole body weight was used.
The estimate of lean body mass was obtained as follows: the
red cell volume (RCV) was estimated from height and weight (Nadler,
et al., 1962). The lean body mass (LBM) was then derived from 
the following equation:
RCV - 155.17
LBM - -----------------  (Muldowney, 1957)
52.74
Results
_Desferal test in normal subjects and patients with iron deficiency.
In normal subjects, the basal urinary excretion of iron 
was about 100 fig. per day or less in both male and female subjects*
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The iron content of the urine collected during the administration of 
a 600 mg, dose of Desferal reached a higher level in male subjects 
(range 473 - 1>233 I^ g*/day> mean 838) than in female subjects 
(range 413 - 822 (ago/day, mean 631). On the day after Desferal 
administration the urinary iron excretion was higher than the basal 
value, but much lower than that during Desferal administration 
(Table 16).
In the sideropenic subjects, the basal urinary excretion of 
iron lay below 100 fig. per day. The urinary iron output during a 
single 600 mg. dose of Desferal in both male and female subjects 
(range 365 - 478 fig./day, mean 424 and range 351 - 814 fig./day, 
mean 454 respectively) tended to be lower than in normal subjects 
(Table 17).
In subjects with iron deficiency anaemia, the basal urinary 
excretion of iron was about 100 fig. per day or less in both male 
and female subjects. The urinary iron output during Desferal 
administration tended to be similar or slightly lower than in 
subjects with sideropenia, ranging from 70 to 378 fig. per day ( mean 
238) in male subjects and from 85 to 475 (ig« per day (mean 320) 
in female subjects (Table 18).
For reasons given earlier, it was considered important in these 
three groups - normal, sideropenic and iron deficiency anaemic - to 
relate the urinary iron excretion, during the administration of a 
standard dose of Desferal to lean body mass.
The urinary iron excretion of normal, sideropenic and iron
Urinary iron fig./24 hrs.
Normal
Males
Normal
Females
Before During After
No* Desferal Desferal Desferal
1 43.7 1233 306
2 41.6 852 158
3 38.7 594 155
4 63.0 593 199
5 84.0 473 mm
6 86.7 867 -
7 91.8 1144 -
8 55.5 945
1 104.0 584 146
2 79.2 415 m
3 66.3 654 136
4 96.0 459 mm
5 56.4 720 -
6 54.0 730 I64
7 67.3 645 -
8 62.7 663 #»
9 75.1 617
10 44.2 822 **
TABLE 16
test in normal subjects:urinary
excretion of iron before, during and after 
one 600 mg. dose of desferrioxamine B 
mesylate*
Urinary iron }ig./24 hrs0
Before During After
No. Desferal Desferal Desferal
Iron 1 94.0 327 -
Deficiency 2 74.0 69.4 m
Anaemia 3 52,5 111 -
Males 4 83.5 308 153
5 68.7 376 mm
Iron
Deficiency
Anaemia
Females
1 92.9 311 115
2 28.3 275 130
3 13.2 354 191
4 97.0 581 209
5 64.2 370 97.6
6 92.0 318 188
7 - 255 122
8 93.1 284 75.5
9 73.5 197 65.8
10 56.0 361 86.7
11 31.8 85.0 67.0
12 42.7 118 -
13 94.0 320 -
14 109.0 437 -
15 38.0 254 -
16 38.5 357 106
17 89.2 276 108
18 55.9 387 74.4
19 48.5 475 475
20 89.6 326 mm
21 40.6 244 -
22 40.2 379 119
23 48.0 391 -
TABLE 18
Desferal test in patients with iron deficiency 
anaemia; urinary excretion of iron before, during 
and after one 600 mg. dose of desferrioxamine 
B mesylate*
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deficiency anaemic subjects during the administration of 600 mg, 
of Desferal was expressed as ^g. iron in 24 hours/kg, lean body 
mass (Tables 19, 20 and 21 respectively) and are shown in Fig. 31•
The mean value of urinary iron, expressed as (ag, in 24 hours/kg, 
lean body mass, and the standard deviation for each group is given in 
Table 22.
In both male and female subjects, the urinary iron excretion 
(expressed as p,g. iron in 24 hours/kg. lean body mass) of the 
sideropenic group lay between those of the normal and the iron 
deficient group. In male subjects, there was no overlap in the 
urinary excretion of iron (expressed as jig. iron in 24 hours/kg. 
lean body mass) between any two of the three groups under study.
In female subjects, there was an overlap in the urinary iron output 
(expressed as \ig, iron in 24 hours/kg, lean body mass)in all three 
groups (Fig. 31),
Using the Student1s t test, the mean urinary iron excretion 
(expressed as (ig, iron in 24 hours/kg. lean body mass) between any 
two of these groups, both male and female, were found to be 
significantly different from each other (p < 0.01) (Table 23).
The Desferal test was also carried out in one patient with 
sideroblastic anaemia and in two with cutaneous hepatic porphyria 
(Table 24).
In all three cases, the basal urinary excretion of iron was less 
than 100 (ig./day. The female patient with sideroblastic anaemia gave 
a response to Desferal above the normal range shown in Table 16, 
proving that previous iron therapy to raise the haemoglobin level,
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Figure 31. Desferal Test in normal subjects (a), 
and in patients with sideropenia (b) and iron 
deficiency anaemia (c).
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Groups t p
Male Normal.and Sideropenia 3<*91 <0,01
Sideropenia and iron ,
, . . 3*o7 <0,01deficiency anaemia
Normal and iron 
deficiency anaemia 5.48 <0.001
Female Normal and Sideropenia 3*94 <0o001
Sideropenia and iron 
deficiency anaemia
Normal and iron 
deficiency anaemia 7.60 <0.001
TABLE 23
The significance of a difference in the mean urinary 
iron excretion (expressed as pg. iron in 24 hours / kg. 
lean body mass) between any two of the following groups 
normal, sideropenic and iron deficiency anaemic - in 
both male and female subjects was calculated using the 
Student*s t test.
Urinary iron |ig./24 hours
Before During
Desferal Desferal
Sideroblastic anaemia 73.5 1061
Cutaneous hepatic porphyria 66.2 1223
tt it it 75*1 532
TABLE 24
Desferal test: urinary excretion of iron before and during 
one 600 mg. dose of desferrioxamine B mesylate*
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had. served only to increase the storage iron above normal, (in 
sideroblastic anaemia, due to a defect in protein metabolism, 
the synthesis of haem synthetase is depressed and this limits the 
production of haemoglobin). In cutaneous hepatic porphyria, the 
urinary response to Desferal of 1223 and 532 (ig. of iron per day 
fell within the normal range found for male and female subjects 
respectively*
Desferal test in states of iron overload
The results of the Desferal test in patients with iron
overload are given in Table 25. Except for two patients with 
paroxysmal nocturnal haemoglobinuria, the basal urinary iron 
excretion ranged from 30 to 146 f-ig. per day. The mean basal urinary
iron excretion in normal subjects and in patients with siderppenia,
iron deficiency anaemia and iron overload are shown in Table 26.
a) Primary idiopathic haemochromatosis
Cases 1, 2 and 3 were untreated. Case 4 was partially 
treated. Case 5 had received repeated venesections totalling 
50 pints of blood, over a period of two years. In cases 1 - 4» 
the urinary iron excretion rose from very low basal levels to over 
3>000 (ig. per 24 hours during Desferal administration; in the fifth 
(treated) case, the urinary iron output during Desferal administration 
was normal (Table 25)*
b) Focal iron overload
i) Paroxysmal nocturnal haemoglobinuria
In this condition, there is heavy deposition of iron in 
the kidney (renal haemosiderosis) (Crosby, 1953)* Both patients
Urinary iron excretion |ag./24hrs. 
Basal
Normal (mean of eighteen subjects)
Primary idiopathic haemochromatosis 
(untreated), Case 1.
Primary idiopathic haemochromatosis 
(untreated), Case 2.
Primary idiopathic haemochromatosis 
(untreated), Case 3»
Primary idiopathic haemochromatosis 
(partially treated), Case 4»
Primary idiopathic haemochromatosis 
(treated), Case 5*
Paroxysmal nocturnal haemoglobinuria, 
Case 1.
Paroxysmal nocturnal haemoglobinuria, 
Case 2.
Idiopathic pulmonary haemosiderosis
70 + 19m
84
146
88
78
30
4,000
16,100
75
During 600 mg. 
Desferal
719 + 233
4,800
8,800
10,600
3,600
631
9,000
22,800
1,600
TABLE 25
Desferal test in states of iron overload
No. Subjects
Mean ur inary  
iron ou tpu t  Standard
(/ /g 24 hr) dev iat ion
9 N o rm a l  males 69 -  19-2
1? N o rm a l  females ' 4 r  22-6
6 Sideropenic males 62 r  7-6
12 Sideropenic females "2 -  23-3
6 I ron deficiency anaemia males 76 -  15-7
25 Iron deticiencv anaemia females 67 r  33-2
5 Id iopath ic  haemochromatosis 55 - 3 7
1 Sideroblastic  anaemia ■u -
2 Cutaneous hepatic porphvr ia "1 -  4
1 Id iopath ic  pu lm onarv haemosiderosis ~s
TABLE 26
Lie an urinary iron excretion in normal subjects 
and in patients with sideropenia, iron 
deficiency anaemia and iron overload.
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were cxcr-eting large ou&ntities of iron vitnout any provocative 
tost (Taole 2p). After the administration of Desferal, trere van 
a. consiccrahlu increase in the aaily urinary iron outout, from 
4,DOC to ' ),OO'O no;, and from lc,100 to 22,BOO up. resx-ectively.
..nenoyiobin, ferri tin ani u. etiosidv,-rin iron v.as estimated, 
in trie urine of sot:'. th<u:e- eatlento (Tar re f 7) • •. Ca.se 1 hod been 
givten Desicral; Case 2 was piv-.ni no Desforai ). in botn cases,
th< n.jor .art of the iron was ox ere tea as . *aorcsiuorin. The
: res. - c,. o: i.nrg- amounts of urinary nnomosiderin was confirmed 
ov staining tne ^r:nary tr-uosit with nciaiif -.a nctnssinm
ferricyanide (Prussian biue reaction).
Urinary iron (np./?4 hr.)
Case 1 Case 2
Iron in haemoglobin 2,100 600
Iron in nacuosidorin 1,400 10,000
Iron in ferritin i,f00 5,500
Total iron H£00 16,100
TABLE 27
Urinary iron excretion in two patients with paroxysmal 
noc nornal ilaomoglobinuria•
ii ) Idio/o.tnic ouimonary haemos 1U ero s is
Tiny Desferal test (Table 25) showed a rise in the urinary
iron excretion from its insigni fi cant basal level to 1,600 ug«/2/j. nours,
Long-term Desferal tiiorany. In idicoatnic pulmonary 
haemosiderosis, the accumulation of iron in the lungs may lead to 
massive fibrosis. for this reason, the nationt was given intermittent 
Desferal treatment over a period of 256 days. (Pips. f2 a and b). 
Initially the patient was given Desferal therapy in hospital over a 
60 day period, with a 10 day rest after 31 days. A dose of 600 mg.
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of Desferal produced a significant sustained increase in the urinary- 
iron excretion. When the dose of Desferal was increased to 
1,000 mg. per day (given as 500 mg. twice daily), the urinary 
excretion of iron doubled in value. After a 10 day rest, Desferal 
therapy was resumed. The urina,ry iron excretion steadily increased 
until more than 6 mg. of iron was being eliminated. Following 
this period of treatment and observation, during which no ill 
effects were noted, the patient was allowed home. Desferal 
treatment was continued, administered by district nurse, and it 
appeared from Fig. 32a that the high level of iron excretion ( 6mg. 
daily) was sustained over the following 30 days. From day 90 to 
day 256 the patient was given Desferal daily for three weeks in 
every four. He was admitted to hospital for one of these three 
weeks for urine collection.
On day 256, Desferal treatment was terminated due to a mild
recurrence of iron deficiency. The total iron removed during the
period of therapy was calculated to be 0.86 g. Where the patient
was on treatment but not on collection of urine, the calculation was
based on the iron output of previous seven days. No figure was
included for periods of non-treatment.
9. Urinary excretion of protein and iron in 
patients with proteinuria.
Clinical cases
Ten of the twelve patients with proteinuria were suffering from 
the nephrotic syndrome. In Case 12, the disease was in partial 
remission (Table 28).
U rina ry U r ina ry U r ina ry U r in a ry
Case Age Diagnosis iron prote in a lbum in /Uglobul in
(> r ) (//g 24 hr) (g 24 hr) (g 24 hr) (g 24 hr)
1 19 N eph ro t ic  syndrome (renal arm lo idos is ) 596 41 3-2 0-38
N eph ro t ic  s_\ ndrome 267 10-2 9-3 0-9
3 15 N eph ro t ic  s\ ndrome 272 10-2 9-41 0-79
301 9-5 8-64 0-87
4 10 N eph ro t ic  syndrome 143 3-02 2-44 0-58
5 19 N eph ro t ic  syndrome 994 100 7-98 1 -26
6 18 N eph ro t ic  syndrome 480 8-6 8-04 0-56
7 40 N eph ro t ic  syndrome 400 9-56 8-57 0-99
8 42 N eph ro t ic  s \nd rom e 188 5-7 5-20 0-50
9 42 Neph rot ic syndrome 86-9 6-85 6-50 0-35
10 51 C hro n ic  g lomeru lonephr i t is 78-3 5-18 5-18 0
11 OS D \spro te inaem ia 68-6 1-4 1-4 0
12 9 N eph ro t ic  s\ nd rome (treated) 77-6 2-75 2-75 0
TABLE 28
The urinary excretion of iron 
and protein in twelve patients 
with proteinuria0
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Plan of study
24 hour collections of urine were made in iron-free containers. 
The total (mixed) protein was determined by the method of Lowry 
et al., (l95l)« Horizontal paper strip electrophoresis of dialysed 
concentrated samples of urine were carried out to determine the 
relative amounts of albumin and °^ ~29 ft &l°bulins present.
Iron was estimated by the method described earlier except that 
initially, during concentration of urine, additional U N  nitric 
acid was required to convert heat coagulated proteins to more 
soluble substanceso 
Results
Pig. 33 shows the separation of urinary proteins in Case 5 
by paper strip electrophoresis. Albumin is the fastest running 
component and is followed by globulins respectively.
Albumin was the major protein fraction present as can be seen from 
the intensity of the band and from the area under the peak of the 
scan. and0^  globulins were present although it was not possible
to estimate either separately. Only one other patient had and oC^ 
globulins present in urine (Case 1). Since the globulin fraction 
was not completely separated from the o4-^ oC ^  globulins, the lowest 
point on the scan between the two fractions was taken as the 
dividing line. The ratio albumin: 2 globulin* |3 globulin was
found to be 202:19:32 by determination of the area under the 
corresponding peaks of the scan. Since the sum of the three areas 
is equal to the total protein, 10.0 g. / 24 hour urine, the absolute
ORIGIN
GLOBULINS A l b u m i n
U*«vCf-i
Figure 33* Separation of urinary proteins in Case 
5 by paper strip electrophoresis. The photograph of 
the stained protein fractions and the corresponding 
scan, drawn using the E.E.L* Scanner, are shown.
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value of each protein component can be calculated.
The iron and protein content of urine in Cases 1 - 1 2  are 
listed in Table 28. The absolute quantities of albumin and 
(8 globulin, calculated from the relative quantities found, are 
also given.
The urinary excretion of iron in Cases 9 - 1 2  lay below 100 \±g»J 
day. In three of these four cases, no globulin was detected in 
the urine. The highest output of urinary globulin co-incided 
with the highest output of urinary iron (Case 5) (Table 28). There 
was a significant correlation between the log of the 24 hour 
urinary excretion of iron and yB globulin (r « + 0.80, p < 0.01)
(Fig. 34). The correlation between the log of the 24 hour urinary 
excretion of iron and total urinary protein was not significant 
(r - + 0.64> p < 0.05)*
10. The effect of a phenylhydrazine-induced haemolysis 
on the urinary excretion of iron during Desferal 
administration.
Clinical data
Cases 1 - 1 0  all had forms of iron overload. Seven of the 
patients had primary idiopathic haemochromatosis, six untreated and 
one (Case 7) treated. (The latter patient was included in the previous 
study as Case 5)» The remaining three patients had cutaneous 
hepatic porphyria with haemosiderosis, sideroblastic anaemia and 
idiopathic pulmonary haemosiderosis respectively (Table 29).
(The last patient was included in the previous study).
log
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yS'Globulin
Figure 34. Correlation of iron and 8 globulin 
in the urine of tv'eJn/v patients with proteinuria. 
Correlation coefficient r = +0.80, p<0.01.
Case
No*
1
Diagnosis
Primary idiopathic haemochromatosis (PIH)
Urinary iron 
jjg./24 hrs.
A B 
41 13,^50
2 P.I.H. 124 10,525
3 Cutaneous hepatic porphyria with 
haemosiderosis 193 12,078
4 P.I.H. 40 2,002
5 P.I.H. 452 16,038
6 Idiopathic pulmonary haemosiderosis 75 3,439
7 P.I.H. (treated) 28 570
8 Sideroblastic anaemia I64 3,773
9 P.I.H. 298 8,785
10 P.I.H. 647 20,728
A (before) and B (during) administration 
of 1,000 mg. Desferal*
TABLE 29
Desferal test in ten patients with iron storage disease*
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Phenylhydrazine was used as the haemolytic agent in a dose of 
100 mg. per day in Cases 1 - 8. This dose was used initially since 
it has been extensively employed in the past without any untoward 
effect for the treatment of patients with polycythaemia vera (Wintrobe, 
1961). In Cases 9 and i0, phenylhydrazine was given in a daily 
dose of 75 nig. A second course of phenylhydrazine treatment of 
50 mg./day was administered to cases 2 and 5«
Phenylhydrazine was given orally in 2^ mg. tablets, two, 
three and four times per day dependent on dose. In all cases,
Desferal was given in twice daily intramuscular injections of 
500 mg. each.
Plan of study
In each case, 24 hour specimens of urine, for iron estimation, 
were collected before and during the period of treatment. Haemoglobin, 
reticulocyte count and serum bilirubin were measured before and 
after treatment as detailed below.
Cases 1 - 8  were given 1,000 mg. of Desferal daily for two 
/days, 100 mg. of phenylhydrazine daily for two days and combined 
therapy of 1,000 mg. of Desferal and 100 mg. of phenylhydrazine 
daily for three days. Using the same plan of study, a further 
investigation using a smaller dose of phenylhydrazine (50 mg*/day) 
was carried out in Case 2 and Case 3» In Cases 9 and 10, 'two days 
of Desferal therapy (l,000 m6./day) were followed by combined 
Desferal (1,000 mg./day) and phenylhydrazine (75 mg./day) therapy
109
for six days.
Results
The urinary iron excretion before and during Desferal 
administration in Cases 1 - 10 is given in Table 29. In the 
previous topic, the maximum basal urinary iron output in 6 patients 
with states of iron overload was 146 (j.g0/day. From Table 29, only 
five of the ten patients have values below 146 (j.g. iron per day.
It is apparent that until information is available from a greater 
number of patients, no generalisation with regards to the basal 
urinary iron output in states of overload should be made. However, 
it is of interest to note that the two patients with the highest 
basal urinary iron excretion, 452 and 647 DS* per day, recorded the 
highest urinary iron output during Desferal treatment, 16,038 and 
20,728 p,g. per day respectively. Compared to the latter two 
figures, the basal excretion of iron in both cases are insignificante 
100 mg. dose of phenylhydrazine
The effect on the urinary iron excretion of a 100 mg. dose of 
phenylhydrazine administered during Desferal treatment in Cases 1 - 
8 is shown in Table 30* In all cases, after two days of Desferal 
treatment, the administration of phenylhydrazine alone for two days 
did not maintain the high urinary iron output. It dropped markedly 
on the first and again on the second day of phenylhydrazine treatment 
(see Table 30). When Desferal was given in combination with 
phenylhydrazine (100 mg./day) the urinary iron output in all cases 
on the first day of treatment exceeded the urinary iron output on the 
first day of Desferal (only) treatment. The mean urinary iron
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excretion during Desferal treatment and the mean during the 
administration of both Desferal and phenylhydrazine for Cases 
1 * 8  are shown in Table 31*
In patients with untreated primary idiopathic haemochromatosis, 
the results in Table 31 show that when phenylhydrazine is given 
during Desferal therapy, a further 42 - 178$ increase in the urinary 
iron excretion is recorded. In the three patients with treated 
primary idiopathic haemochromatosis, idiopathic pulmonary 
haemosiderosis and sideroblastic anaemia, there was no significant 
increase in the urinary iron output when phenylhydrazine was given 
during Desferal therapy (Table 31)*
In all patients given 100 mg. of phenylhydrazine daily, the 
haemoglobin level did not fall below 12.5 g*$ except in the patient 
with sideroblastic anaemia whose haemoglobin remained at 11 g.$ even 
after phenylhydrazine treatment.
75 mg* dose of phenylhydrazine
The urinary iron output in Cases 9 and 10 on treatment with 
Desferal alone and in combination with phenylhydrazine ( 75 mg./day) 
are shown in Table 32. In Case 10, the urinary iron excretion 
increased steadily from 18 mg. on the first day to 38 mg. on the 
sixth day of combined therapy. In both cases, there was a further 
significant increase ( mean 44 and 61$) in the urinary iron output 
when phenylhydrazine was given during Desferal therapy.
50 mg. dose of phenylhydrazine
In Cases 2 and 5> the effect, on the urinary excretion of iron, 
of a 50 mg. dose of phenylhydrazine, alone and in combination with
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Treatment Day Urinary iron jig#/ 24 hrs#
Case 9 Case 10
m 1 298 647
Desferal 2 8,785 20,728
(1,000 mg#/day) 5 18,219 17,000
Combined, therapy 4 16,700 18,400
of Desferal 5 21,113 21,960
(1,000 mg#/day) 6 21,512 24,754
and phenylhydra­ 7 25,410 27,666
zine (75 mg#/day) 8 24,480 51,824
9 23,484 37,920
24 hour urinary iron excretion (fjg.) 
onx-
Case Control Desferal+ Desferal and $ increase on
No# Day
9 298
10 647
+ 1,000 mg#/day 
* 75 mg,/day
TABLE 52
(mean of phenylhydrazine* combined therapy
2 days) (mean of 6 days) compared with
Desferal alone
13,502 21,685 61
18,864 27,071 44
24-hour urinary iron excretion in Cases 9 10 during treatment
with desferrioxamine B mesylate alone and in combination with 
phenylhydrazine (75 mg#/day).
Ill
Desferal, is shown in Table 33* In Case 2, during combined 
Desferal and phenylhydrazine therapy, the urinary iron excretion 
rose steadily over the four days of treatment, the mean daily 
excretion being 14,874 l-ig* compared to a mean, during Desferal 
administration alone, of 10,319 H-g* ie» a 44$ increase on combined 
therapy. In Case 5, the rise in the urinary iron output on 
combined therapy was not sustained over the four day treatment 
period. There was only a 6$ increase in the urinary iron excretion 
over that found during Desferal administration alone.
In Case 2, 50 mg. and 100 mg. of phenylhydrazine given during 
Desferal treatment resulted in further increase of 44$ and 42$ 
respectively in the urinary iron output. On the other hand, in 
Case 5, 50 mg. and 100 mg. of phenylhydrazine given during Desferal 
treatment resulted in further increases of 6$ and 108$ in the urinary 
iron output (Tables 31 and 33)*
The initial reticulocyte count in all patients was less than 
2$. After phenylhydrazine treatment it was raised in four cases to 
2 - 4$« The serum bilirubin was increased in all but one patient 
but in no instance was the value greater than 3*5 mg./lOO ml.
(Normal range 0.05 - 0.24 mg./lOO ml., mean 0.1. Documenta Geigy, 
1962).
Section C.III DISCUSSION
The present studies of the basal urinary iron output confirm 
those of Cartwright et al., (1954) and contradict those where higher 
values have been obtained (Tepe, 1953)• Such high values may be 
accounted for by external contamination with iron during collection
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or laboratory procedures (^Bothwell and finch, 1962, p. 121).
The urinary losses of iron in normal, sideropenic and iron 
deficient subjects appear to be uninfluenced by the body iron 
content, being approximately 100 (j,g. or less daily. In states of 
iron overload the urinary losses may vary, apparently to some 
extent dependent on the tissue iron stores. Eleven of the fourteen 
patients excreted less than 200 |ig. of iron daily, 647 being the 
highest daily excretion.
The nature of the physiological urinary iron losses is uncertain. 
In normal subjects, 0 - 9 0  mg. of protein in 24 hours may fail to be 
reabsorbed from the glomerular filtrate and it is possible that small 
urinary losses of transferrin may thus occur, finch (1964) has 
found as much as 1 mg. daily of transferrin in the urine of 
normal persons. Other possible sources of urinary iron are 
desquamated urinary tract cells, and the physiological urinary loss 
of erythrocytes; accepting a normal excretion of not more than
200,000 erythrocytes per hour (Gadeholt, 1964), the daily excretion 
of iron from this source is approximately 0. 5
Increased urinary losses of iron were found in patients with 
proteinuria, confirming the findings of Cartwright et al., (1954) 
and Rif&ind et al., (j.961). Whereas the relation between urinary 
iron and total urinary protein was not significant, the relation 
between iron ana yB globulin was significant. This confirms the 
findings of Rifkind et al., (1961) and suggests that the renal leak 
of transferrin is responsible for the increased urinary iron 
excretion. The urinary losses of iron and transferrin account for
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the low concentrations of these substances found in the serum 
of severely proteinuric patients, and the iron deficiency state 
resulting from such losses may contribute to the anaemia of nephrosis.
It is of interest that one of the patients studied had an absence of 
stainable iron in the marrow; she made a partial response to oral iron 
therapy, the naemoglobin level rising from 6.7 to 10,3 in w o  
months•
The two patients with paroxysmal nocturnal haemoglobinuria 
excreted large quantities of iron daily in the urine. Both patients 
had an absence of stainable iron in the bone marrow and a hypochromic 
blood picture, although this latter finding has been stated by 
Crosby (1955) to be rare.
The urinary iron excretion during Desferal in both sideropenic 
and iron deficiency anaemic patients was reduced when compared with 
normal subjects. The urinary iron output appears therefore to reflect 
the tissue iron depletion found in these states. There was however some 
overlap between normal.and iron deficient subjects in the urinary 
iron excretion during Desferal. This was also found by Fielding 
(1965) using a differential ferrioxamine test. It has been assumed 
that before anaemia develops in states of iron deficiency, there 
must be complete depletion of the tissue iron stores (Bothwell and 
Finch, 1962, p. 281). The increased iron output during Desferal in 
the iron deficient patients suggests that some ferritin, which does 
not take up marrow iron stain, is still present.
In the patients with untreated primary idiopathic haemochromatosis, 
large quantities of iron were excreted following a single dose of
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Desferal. It is of interest that the urinary iron output in 
the treated case was normal. Desferal is of limited value in the 
treatment of primary idiopathic haemochromatosis but the Desferal 
test is useful not only in confirming the diagnosis, but also in 
assessing the effectiveness of iron removal by venesection. It 
may also be of use in detecting iron overload in relatives of 
patients (Bannerman et al., 1962).
The two conditions associated with focal iron overload are 
characterised by heavy deposition of iron in specific organs, i.e. 
in the kidneys in paroxysmal nocturnal haemoglobinuria and in the 
lungs in idiopathic pulmonary haemosiderosis. In both instances, 
there co-exists generalised iron depletion leading, especially in 
pulmonary haemosiderosis, to severe iron deficiency anaemia. The 
two patients with paroxysmal nocturnal haemoglobinuria excreted even 
more iron in the urine when Desferal was given; presumably this 
additional iron had been mobilised from the kidneys. Desferal also 
induced an increase in iron excretion in the patient with idiopathic 
pulmonary haemosiderosis. This increase was much greater than 
would be expected in a severely iron deficient patient or even a nor­
mal subject. It is of interest that the iron deposits in the lungs, 
which are not available to the body for haemoglobin synthesis, were 
able to be mobilised by Desferal. Renal haemosiderosis has not been 
reported to cause renal insufficiency (Crosby, 1953) and there is 
thus no indication for Desferal therapy. In idiopathic pulmonary 
haemosiderosis, on the other hand massive lung fibrosis may occur 
with fatal results. For this reason, treatment with Desferal in this 
patient was continued for over nine months in an attempt to mobilise
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iron from the lungs. This resulted in 0.86 g. of iron being 
removed.
In seven patients with untreated haemochromatosis or haemosid­
erosis, the effect of a mild phenylhydrazine-induced haemolysis on 
the urinary iron excretion during Desferal treatment caused a 
further significant increase in the iron excretion of 42 - 178%.
The precise mechanism by which more iron is made available for 
chelation is not known. Chelation of iron by Desferal may be 
furthered at one or more of the following stages: (l) when iron
is released from the protoporphyrin linkage; (2) when The 
stimulation of erythropoiesis by haemolysis provokes the mobilisation 
of iron from the depot stores of haemosiderin. It has not yet been 
established whether, as a result of haemolysis, the level of plasma 
ferritin is raised. If proven, such an increase would make available 
a form of iron which is readily chelatable by Desferal.
An insignificant rise in the urinary iron excretion was recorded 
when three patients with idiopathic pulmonary haemosiderosis, treated 
idiopathic haemochromatosis and sideroblastic anaemia were given 
phenylhydrazine during Desferal therapy. In idiopathic pulmonary 
haemosiderosis, the iron deposited in the lungs is not available for 
haemopoiesis and this may explain the failure of phenylhydrazine, in 
combination with Desferal, to further increase the urinary iron 
excretion. The male patient with -created primary idiopathic 
haemochromatosis had depleted iron stores as a result of repeated 
venesections. In sideroblastic anaemia, there is usually some degree 
of haemolysis present and this would reduce the effect of phenylhydrazine
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on the urinary iron output during Desferal therapy.
In animal experiments, Keberle and Goldberg (1965) have 
demonstrated an increase in both faecal and urinary iron excretion 
on combined Desferal and phenylhydrazine therapy. The increase in 
the faecal excretion of iron may be related to the induced 
haemolysis, since it has been shown in dogs that a phenylhydrazine- 
induced haemolysis can provoke a striking increase in the biliary 
iron excretion (Dubach et al., 1955)* Enhanced faecal excretion 
of iron was demonstrated when patients with transfusional siderosis 
were given Desferal (G-evirtz et al., 1965). Further studies are in 
progress to investigate the faecal excretion of iron, in patients 
with iron overload, during treatment with Desferal alone and in 
combination with phenylhydrazine.
Although the value of Desferal as a specific chelator of iron 
is widely recognised, the therapeutic relevance of its use in 
combination with phenylhydrazine cannot yet be defined. Not only 
is it necessary to assess the total daily iron excretion in both 
faeces and urine during combined therapy, but the frequency and 
the degree of haemolysis which may be safely undertaken, using 
phenylhydrazine, must be determined. If the faecal and urinary 
excretion of iron exceeds 200 mg. per week and if repeated courses 
of mild haemolysis may be safely undertaken, then combined Desferal 
and phenylhydrazine therapy may provide an alternative to 
venesection in the treatment of iron storage diseases.
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Summary
The 24-hour urinary excretion of iron has been measured in 
twenty-two normal subjects, in eighteen patients with sidexopenia, 
in thirty-one patients with iron deficiency anaemia and in fourteen 
patients with various forms of iron overload. In stat® of iron 
overload, eleven of the fourteen patients excreted less than 200 fig. 
of iron daily in the urine (Maximum found 647 fig./day). In all 
other patients and in normal subjects, 100 (ig. of iron or less was 
excreted daily.
Patients with proteinuria and paroxysmal nocturnal haemoglobin­
uria may excrete iron much in excess of this. In twelve patients 
with proteinuria, up to 1 mg. of iron was lost each day in the 
urine; a good correlation was found between the urinary output 
of iron and of ^ 6 globulin, confirming the view that excessive 
losses of transferrin are responsible for the increased urinary 
iron excretion in such patients.
Two patients with paroxysmal nocturnal haemoglobinuria excreted 
daily up to 5 and 20 mg. of iron respectively in the urine. The 
major portion of this iron was lost as haemosiderin, ferritin and 
haemoglobin accounting for the remainder; these losses were 
associated with an iron deficiency state in both patients.
The 24-hour urinary excretion of iron following a single 
intramuscular injection of 600 mg. of Desferal was measured in 
normal subjects and in patients with iron overload and iron 
depletion. Patients with untreated or partially treated
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haemochromatosis had considerably greater urinary iron excretion 
following Desferal than normal subjects. The urinary iron output 
following Desferal in sideropenia and iron deficiency anaemia was 
reduced, reflecting the tissue iron depletion found in these states.
It was notable that the mean iron output in the sideropenic group 
was less than in the normal subjects, but greater than in the 
patients with frank iron deficiency anaemia.
Two patients with paroxysmal nocturnal haemoglobinuria and one 
with idiopathic pulmonary haemosiderosis excreted excessive increments 
of urinary iron following Desferal, although each of these three 
patients had iron deficiency anaemia.
The long-term use of Desferal for the treatment of patients 
with iron storage disease has hitherto been of limited value because 
it generally removes, in the urine, no more than 20 mg. of iron per 
day. The effect of a mild phenylhydrazine-induced haemolysis on 
the urinary excretion of iron has been studied in ten of these patients.
There was a 42 - 178% increase in the urinary iron excretion when 
seven patients with untreated iron-storage disease (six with primary 
idiopathic haemochromatosis and one with cutaneous hepatic porphyria 
and haemosiderosis) were given phenylhydrazine during Desferal 
treatment. There was no significant increase in the urinary iron 
excretion when phenylhydrazine was given to three patients with 
treated primary idiopathic haemochromatosis, sideroblastic anaemia and 
idiopathic pulmonary haemosiderosis on Desferal therapy.
The doses of Desferal and phenylhydrazine administered were
1,000 mg. and 100 mg. respectively per day. There was a transient
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haemolytic anaemia in one patient given the latter dose for 
fourteen days, so further studies were carried out using smaller 
doses. Daily 75 mg* doses of phenylhydrazine given during 
Desferal therapy, produced a significant increase in the urinary 
iron excretion (p < 0.01).
It is not yet possible to define the therapeutic applications 
of these observations to the long-term management of iron-storage 
disease. It is necessary to assess the combined faecal and urinary 
iron output as well as the frequency and degree of haemolysis which 
may be safely undertaken.
PART D. THE EFFECT OF IRON ON FERRITIN 
SYNTHESIS IN RAT INTESTINAL MUCOSA
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Section D.I INTRODUCTION
The isolation from mammalian spleen, of a brown iron-containing 
compound by Laufberger (1934)* occurred during a period of intense 
interest and fruitful research into the problems of the absorption, 
excretion and transportion of iron by the body. Laufberger named 
this iron storage compound ferritin.
In the 1930fs it was shown that approximately 20-25$ of iron 
in the body was in a storage form and was present mainly in liver, 
spleen and bone marrow (Hahn, 1937)- It was appreciated that 
the storage iron did not appear to participate in active metabolic 
processes but represented a reserve, which varied from person to 
person, mobilisable for haemoglobin synthesis when required (Hahn,
1937).
Storage iron is found in two forms, ferritin and haemosiderin.
o
Ferritin is a water soluble protein, stable at 80 C in near neutral 
solution. It is precipitated by half saturation with ammonium 
sulphate and may be crystallised as the cadmium salt (Laufberger, 
1935* 1937; Granick, 1942). Ferritin consists of a homogeneous 
protein, apoferritin with a molecular weight of 465*000 (Rothen, 
1944) and an iron containing fraction, present in the form of
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inorganic micelles. The latter appears to be made up of ferric
hydroxide-phosphate complexes, with the empirical formula
(FeOOH) (FeO: PO H ) (Granick & Hahn, 1944)- The presence 
o j 2
of electron dense clusters of iron atoms in the ferritin mole­
cule has been demonstrated by electron microscopy, the clusters 
being arranged in regular well defined patterns, apparently 
based on a structure common to all the molecules (Farrant, 1954; 
Kerr & Muir, I960). The structure of■ ferritin is that of a 
protein shell (apoferritin) covering an iron-containing core 
(Hofman & Harrison, 1963)- Ferrous iron can be incorporated 
directly into apoferritin (Bielig & Bayer, 1955) and the 
resulting ferritin may contain up to 23% of its dry weight as 
iron (Granick, 1946 b).
Haemosiderin has long been recognised, its granular 
particles being demonstrable in tissue preparations by the 
Prussian blue reaction (Peris, 1888). It was so named by 
histologists who believed that the granules were a result of 
excessive haemoglobin catabolism (Cook, 1929)- The structure 
of haemosiderin is not defined. Many authors have reported 
the presence of ferritin and proteins in purified haemosiderin
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(Shoden et al, 1953; Richter, I960; McKay and Fineberg, 1958).
In 1961, Shoden & Sturgeon stated that haemosiderin and ferritin 
were not only chemically but also structurally dissimilar and 
suggested that haemosiderin consisted of an amorphous condensation 
of iron particles (mainly ferric hydroxide) in an essentially 
protein-free aggregate- Since the fundamental property which 
distinguishes ferritin from haemosiderin is the solubility of 
ferritin in water (Laufberger, 1934)> they stated that until the 
nature of haemosiderin is established, all non-ferritin (i.e. 
water insoluble) storage iron should be classed as haemosiderin 
for convenience.
Seventy years ago, the presence of Prussian blue staining 
granular deposits in the macrophages of the intestinal villi 
and in the epithelial cells of the small intestine were reported 
in animals given large doses of iron by mouth (Lipski, 1893; 
McCallum, 1894; Hochhous & Quincke, 1896). Early workers 
assumed these to be haemosiderin- (The Prussian blue stain is 
now known to detect not only haemosiderin but also ferritin, 
if present in high concentrations. The stain, however, is much 
less intense (Shoden & Richter, i960). ) Histological demons­
123
tration of iron in the wall of the intestine did not give informa­
tion as to whether the iron was being absorbed or excreted 
(McGowan, 1930) and for many years there was controversy as to 
whether the intestine was able to excrete as well as absorb iron. 
During these years, most of the problems of iron therapy which 
troubled physicians were fundamentally traceable to their 
ignorance of the mechanism by which iron was absorbed from the 
intestinal tract. Clinical observations had shown that simple 
ferrous salts were apparently utilised to a greater extent for 
haemoglobin formation than were complex ferric salts, such as 
ferric ammonium citrate (Heubner, 1924* 1926; Wiechowski, 1927; 
Witt, 1936) but this had not been demonstrated experimentally. 
There was no dependable direct method of measuring the immediate 
absorption of iron into the blood stream from the gastrointestinal 
tract. After Starkenstein & Harvalik (1933) found that ferric 
iron in blood is transported combined with globulin, it was 
demonstrated by Moore et al (1936, 1937) and Heilmeyer & Plotner 
(1937) that plasma iron is of metabolic importance, serving as 
the medium of iron transportation in the mammalian organism.
An index of the amount of iron being absorbed from the gastro-
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intestinal tract can be gained by measuring increases in plasma 
iron (Moore et al, 1939 b).
By 1939, Moore and his co-workers (1939 b) were able, from 
their own studies and by reviewing available literature, to put 
forward the following picture of absorption of oral iron. On 
reaching the stomach, ingested iron is affected by the free 
hydrochloric acid normally present. This tends to ionise and 
dissolve iron not already present in solution. On reaching the 
duodenum, iron is subject to the action of alkaline intestinal 
juices and to the action of reducing agents. The latter tend 
to reduce any trivalent iron to the ferrous form before the change 
to non-ionisable salts occurs. Absorption of iron, in the ferrous 
form, takes place largely in the upper portion of the small 
intestine. When iron is absorbed, it passes directly into blood 
plasma.
At an earlier period, the work of Lintzel (1931) on iron 
metabolism under various conditions tended to show that the body 
could assimilate or reject oral iron depending on the needs for 
iron, a consideration which the work of Fontes & Thivolle (1932) 
on dogs seemed to corroborate. These authors believed that
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the process of iron metabolism was controlled by selective intes­
tinal absorption. It was later assumed that iron metabolism 
was regulated by absorption and not by excretion (Heilmeyer & 
Plotner, 1937; Moore et al, 1939 a). At this time, McCance & 
Widdowson (1937) had come to the conclusion that there was no 
evidence that iron was excreted by the bowel and that iron meta­
bolism was regulated by controlled absorption.
Hahn and his co-workers (1943) were the first to show the 
importance of ferritin in the absorption of iron from the gastro­
intestinal tract. They found that when oral iron was given to 
dogs 1-6 hours before radio-iron, the absorption of radio-iron 
was much depressed. These results led to the concept of a 
Tmucosa block1 in which it was suggested that the mucosal cells 
had the capacity to prevent the excessive uptake of iron.
Hahn and his co-workers considered that the ability of the 
intestine to reject iron was a result of saturation of a physio­
logical receptor such as apoferritin. As early as 1937* Hahn 
had stated that the form in which iron is ingested appeared 
not so important as the unknown intestinal factor or factors 
involved in limiting the absorption and hence the utilization 
of iron.
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Granick (1946 a) showed that when large amounts of iron salts 
were given to guinea-pigs, ferritin accumulated in the mucosal 
cells of the gastrointestinal tract. He used a semi-quantitative 
method for the measurement of the accumulation of ferritin in the 
mucosa which depended on the counting of ferritin crystals under 
a Thigh-dryf or oil immersion lens. Granick considered that 
ferritin played two roles - one facilitating the absorption of 
iron and the other blocking the further absorption of iron, i.e. 
when minimal amounts of iron were available from the lumen of the 
gastrointestinal tract, individual ferrous ions could pass through 
the mucosal cells and into the bloodstream. With increasing 
amounts of iron available, apoferritin was synthesised and 
ferritin was formed in the mucosa of the small intestine. If 
much ferritin was formed, it blocked the passage of iron through 
the mucosa ("mucosal block”), tending to stop further absorption 
of iron.
From the evidence available, it would appear that normally 
there is little or no apoferritin in the intestinal mucosa but 
that on the administration of oral iron, apoferritin is synthesised 
rapidly in the epithelial cells (Granick, 1946 a; Gabrio & 
Salomon, 1950; Heilmeyer, 1958; Charlton et al, 1963)- The
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parenteral administration of iron has been shown to induce increased 
ferritin synthesis in liver (Fineberg & Greenberg, 1955 a; Drys- 
dale & Munro, 1966). This suggests that iron may stimulate the 
synthesis of a specific protein in a manner analagous to that in 
which an injected antigen provokes the production of antibody 
protein. That iron and apoferritin seem intimately related is 
further illustrated by the findings that the levels of apoferritin 
decrease when iron is mobilised from the tissues by bleeding 
(Granick, 1943)- Heilmeyer (1958) has shown that ferritin serves 
as a mediator of iron absorption in the gastrointestinal tract 
but believes that an as yet unknown regulator of iron uptake exists. 
Keiderling & Wohler (1954) have shown, in guinea-pigs, that at 
the time of maximal ferritin content in the duodenum, on the 
tenth day of iron feeding, iron absorption was still clearly 
going on, so that a total mucosal block was certainly not present. 
This was confirmed by the results of Heilmeyer (1958). He 
found that on feeding guinea-pigs iron daily, there was a good 
absorption of iron until the 14th day after which there was no 
increase of iron in the organs. He stated that this may be 
interpreted to mean saturation of the organs coincidental with
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decreasing absorption for at the same time, there was a decrease 
in the ferritin content of the small intestine. Haemosiderin, 
which was at first only chemically demonstrable, was formed along 
with ferritin in the intestinal mucosa. As the absorption of 
iron increased, histochemically demonstrable haemosiderin was 
formed in the interstitial tissue rather than in the epithelium. 
On the basis of his studies and those of Keiderling & Wohler, 
Heilmeyer (1958) proposed a new hypothesis modifying that of 
Granick (1946 a):- When iron enters the mucosal cell, it may 
be stored as ferritin or haemosiderin. By means of a reducing 
substance, ferritin is broken down and the ferrous ions released 
leave the cell and pass into the bloodstream where they are 
transported by transferrin. Whether haemosiderin or ferritin 
is formed depends on the amount of iron administered and the 
duration of the cellular iron uptake. With large doses, iron 
is stored briefly as haemosiderin and later changed to ferritin. 
With slow administration, ferritin is formed immediately.
The relatively large amounts of absorbed intraluminary iron 
is diverted to storage in the liver and the intestinal wall,, so 
that the plasma is protected from iron in excess of its binding 
capacity.
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Crosby & Conrad (1963) have shown, by parenteral administration
59
of Fe, how the intestine is able to excrete iron. By auto­
radiography, labelled iron was found initially at the base of the 
villi in the intestinal mucosa. The radio-iron was incorporated 
into newly formed columnar epithelial cells, which migrate over 
a two day period for rats, from the crypts to the tips of the villi. 
There they, and the iron they contained, were lost as the cells 
were desquamated at the end of their life cycle into the intestinal
lumen. Radio-iron was also found in the epithelial cells of the
59intestinal villi when oral Fe was given. Conrad & Crosby (1963) 
suggested that the iron sequestered in the intestinal epithelial 
cells serves ,fnot as an intermediate stage in the absorptive 
process, but as a means of frustrating the absorption of iron 
when it is not needed”. This and other work led Crosby (1963) 
into a general hypothesis on the control of iron balance by the 
intestinal mucosa. He suggested that iron incorporated into the 
epithelial ferritin cannot be released and therefore is lost at 
the end of the three days life cycle of the mucosal cell. He 
noted that when the iron stores were replete the newly forming 
epithelial cells could synthesise apoferritin, thus preventing the
1 .3 0
entry of dietary iron into the body, but that in iron deficiency 
anaemia, the mucosal cells contained relatively little ferritin.
He postulated that in iron deficiency these absorptive cells were 
constructed with ’a relative lack of ferritin’ apparatus so that 
dietary iron can pass freely into the cell and then freely into 
the body. Inherent in this hypothesis is the suggestion that 
there are two types of mucosal cell, one containing "ferritin 
apparatus11 in iron-replete subjects and another with a relative 
lack of "ferritin apparatus" in states of iron deficiency.
Crosby tried to explain the three day lag in iron absorption 
following acute bleeding, by the development of a different type 
of mucosal absorptive cell within that period, a cell which 
would not contain "ferritin apparatus" and thus allow an increased 
entry of iron through it. It would perhaps seem more reasonable 
to assume that the cell in each of these states was similar but 
that its ability to synthesise apoferritin was influenced by 
some factor, for example iron itself. If in fact iron given 
parenterally or even enterally provoked apoferritin synthesis 
in the intestinal mucosa, this could explain many of Crosby’s 
observations. Hitherto, the effect of parenteral iron on
131
ferritin synthesis in the intestinal mucosa has not been elucidated,
although Fineberg & Greenberg (1955 a) and Drysdale & Munro (1966)
14have shown that parenteral iron stimulates the C amino acid incor­
poration into liver ferritin.
In the present study, iron was given orally and parenterally 
to rats and the effect of this was observed on the incorporation
14of C labelled leucine into the ferritin of the gastrointestinal 
mucosa. Small scale isolation of mucosal ferritin was achieved 
by using a specific antiserum prepared by injection of horse spleen 
ferritin into rabbits.
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Section D.II MATERIAL, METHODS AND RESULTS
1. Experimental Animals
a) Rabbits. Five Californian rabbits,, weight 2.3-3-5 kg., 
were used for the production of antiserum. They were given 
injections of iron sorbitol citric acid at intervals, dependent 
on the volume of blood removed, to safeguard against possible 
iron deficiency.
b) Rats. Rats were obtained from a standard colony and were 
delivered by rail. To ensure standard conditions, they were 
kept for one week after delivery before use.
2. Experimental Data
The details of iron and radioactive tracer given to rats in 
each group are given later.
After the rat was killed, its small intestine (from the 
beginning of the duodenum to the beginning of the caecum) was 
removed, washed through with 20-25 ml of 0.9$ w/v sodium chloride 
and gently squeezed to expel the remaining saline. The intestine 
was then slit along its length, cut into short strips and laid 
on a stainless steel sheet. The mucosa was scraped off with
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a microscope slide (Munro & Goldberg, 1964) and weighed- 2-5-4-5 g 
of mucosa were obtained when the animals were given a normal diet 
up to the time of the experiment. Four volumes (w/v) of water were 
used to homogenise the mucosa in a Potter Elvehjem type of homo- 
geniser using a Teflon (polytetrafluoroethylene) piston- The 
homogenate was heated with constant stirring to 80°C (Laufberger,
1937) in a water bath. The heat-coagulated protein was centrifuged 
down and the "heat supernatant fraction", containing heat-stable 
mucosal ferritin was decanted, filtered through No- 1 filter 
paper, centrifuged and decanted to ensure that no particles of 
heat coagulum remained. The method now follows that devised by 
Drysdale & Munro (1965) for the isolation of liver ferritin.
After noting the volume (up to 15 ml), 0-5 ml ferritin antiserum 
(prepared as noted later) was mixed with the "heat supernatant
fraction". (All precipitations were carried out in the presence
\ 0 of excess antibody.) After incubation for one hour at 37 C
and standing overnight at 4°C (Mazur et al, I960), the brown
ferritin precipitate was collected by centrifugation and washed
twice with 3 ml of 0.9^ saline. The precipitate was dissolved in 0.1
ml O.IN.NaOH and made up to 10 ml with deionised water. One
ml samples were removed for duplicate protein estimation and
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iron was determined in the remaining 8 ml. The volume used for
the spectrophotometric reading of the iron estimation was recovered
and combined with the rest before addition of perchloric acid
(PCA) to give a concentration of 0.35N for protein precipitation.
o
After standing for two hours at 4 C, the precipitate was spun
down, washed twice with 3 ml 0.2N.PCA, finally dissolved in O.lN.NaOH
14and mounted on a stainless steel planchette. The activity of C
labelled ferritin was calculated after counting on a gas-flow 
Geiger Counter. (Livers were removed and homogenised as above 
but normally ferritin was isolated from only 2 ml of the "heat 
supernatant fraction" of liver homogenate.)
The specific activity (c.p.m./mg protein) of the heat 
coagulable non-ferritin protein was determined by dissolving a 
small amount in O.IN.NaOH and adding water to a suitable volume 
before estimating protein concentration per ml and activity per 
ml by PCA precipitation as above (Drysdale, 1965)-
3- Determination of Protein
Protein was estimated by the method of Lowry et al (1951) 
as detailed in Section C.II.
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4- Estimation of Ferritin Iron
Ferritin iron was estimated by the addition of 1 ml 0.5$ w/v 
2:2* dipyridyl in 60$ v/v acetic acid and 0.5 ml 1.5M sodium 
sulphite to the sample in a conical graduated centrifuge tube. 
This mixture was heated for one hour in a boiling water bath to 
ensure complete iron extraction. The extinction was read at 
520 mp. after centrifugation of any protein precipitate formed 
(Drysdale & Munro, 1965).
145. Determination of the Activity of C labelled Ferritin 
Protein precipitates were dissolved in O.IN.NaOH and mounted
on discs of lens tissue in order to standardise self absorption
(Garrow & Piper, 1955)- Normally 80-750 p.g of "^C labelled
protein were mounted and counted on a gas-flow Geiger Counter to 
a standard error of 4$ or less.
6. Preparation of Ferritin
a) Isolation and crystallisation
Crystalline ferritin was prepared by the method of Granick 
(1946 b) and Mazur & Shorr (1948, 1950) from fresh horse spleen. 
The spleen was minced, homogenised with lj? volumes of water (w/v)
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and heated to 80 C in a water bath. After centrifugation, the
dark brown supemate containing heat stable ferritin was decanted.
(The precipitate may be extracted with a small volume of water
to remove residual ferritin, before discarding.) The solution
was adjusted to pH 4-6 with 50% (v/v) acetic acid to precipitate
any denatured ferritin and other proteins (Agner, 1943)- The
precipitate was discarded. An equal volume of saturated ammonium
sulphate was added to the solution and it was allowed to stand 
o
for two hours at 4 C. After centrifugation, the supemate was 
discarded and the precipitate extracted with water to dissolve 
ferritin. The ferritin solution was half saturated with ammonium 
sulphate as before and the precipitate was taken up in the 
minimum volume of water. A quarter volume of cadmium sulphate 
was added to the ferritin solution and the ferritin allowed to 
crystallise (0.25 ml of 5-20% w/v cadmium sulphate was added to 
1 ml test solutions of ferritin to determine the optimal cadmium 
concentration required for crystallisation). After a few days, 
the ferritin crystals were collected by centrifugation and 
dissolved in the minimum volume of 2% w/v ammonium sulphate. 
Ferritin was crystallised four times by this process. Finally
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the ferritin solution was dialysed against running water to remove 
the bulk of the cadmium ions. Ferritin was precipitated out of 
solution by the addition of an equal volume of saturated ammonium 
sulphate and washed twice with further volumes of saturated ammonium 
sulphate to further reduce the cadmium concentration. The ammonium 
sulphate was removed by dialysis against 0.9$ saline.
b) Gel filtration
Ferritin was passed through G.200 Sephadex in an attempt to 
remove any remaining toxic cadmium ions (Drysdale, 1965). It has 
since been shown that non-ferritin antigens are present in 
crystalline horse spleen ferritin but that they can be removed 
by chromatography on G.200 Sephadex (Paterson et al, 19&5)-
Sephadex is a modified dextran in the form of minute beads 
which swell considerably in aqueous solution. Molecules larger 
than the largest pores of the swollen Sephadex cannot penetrate 
the gel particles and pass through the bed in the liquid phase 
outside the particles. Smaller molecules however,, penetrate 
the gel to a varying extent dependent on their size and shape.
G.200 Sephadex was made up in 0.9$ saline. Ferritin, 
molecular weight 465*000 (Rothen, 1944) is completely excluded
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from the gel particles. No marker dye was added to the ferritin 
solution since the passage of the brown solution through the gel 
is easily visible. Columns, 6” long and §” diameter, were f rds 
filled with a suspension of the gel. A circle of filter paper 
placed on top of the gel enabled ferritin to be layered on to the 
gel without disturbance. Saline was added when ferritin had 
drained through the surface. Ferritin eluted from the column 
was precipitated by half saturation with ammonium sulphate, 
dissolved in 2% ammonium sulphate and dialysed against 0.9% saline.
c) Gel electrophoresis
The purity of ferritin was checked by polyacrylamide gel 
electrophoresis using Tris(hydroxymethyl)aminomethane(Tris) buffer. 
The latter two compounds are available commercially under the 
trade names cyanogum 41 and Trizma Base respectively.
6.25 ml 1M citric acid and 25 ml 1M Trizma Base were made 
up to 1 litre and the pH adjusted to 6.6 with citric acid. (Buffer 
solution, pH 6.6). The gel buffer was prepared by adding 4 drops 
each of l±0% w/v ammonium persulphate and NsNsN'iN1 tetramethyl- 
ethylenediamine to a 4-5$ w/v solution of cyanogum 41 in buffer 
solution, pH 6.6. (The first two reagents catalyse the setting
139
of the gel.) After air had been extracted by suction pump, the 
gel buffer was poured into a perspex tray, 13 cm by 3 cm. The 
lid was placed in position, excluding all air bubbles, and weighted 
to keep air out. Three perspex squares attached to the underside 
of the lid caused three slits to be formed in the gel on solidifica­
tion (3 hours). The gel was placed on the central compartment 
of the electrophoresis bath and connected to the vessel buffer 
(0.25M Trizma Base) by wicks of double thickness chromatography 
paper, overlapping each end of the gel by 0.5 cm. Ferritin was 
applied into one or more of the slits and a perspex slide placed 
on top of the gel. A constant current of 200 V was passed until 
the yellow band of ferritin was seen to have moved 0.5 cm or more 
from the origin (about 7 hours). After electrophoresis, the 
surface layer was sliced off, using a gel cutter, in order to 
eliminate surface smears. The gel was stained for protein and 
iron simultaneously in a solution of Ponceau S (0.05$ w/v) and 
potassium ferricyanide (0.2$ w/v) in 3$ W Y trichloroacetic acid 
and washed with 5$ v/v acetic acid.
Protein impurities which stain red if present, migrate in 
front of the ferritin bands. The ferritin bands stain blue 
since Prussian blue overstains the red protein stain.
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Results of gel electrophoresis
No protein impurities were seen in any of the ferritin prepara­
tions which had been passed through G.200 Sephadex. In every 
preparation, the electrophoresis pattern of ferritin showed not 
one band but three bands, i.e. 1 major band, followed by 2 minor 
bands. The presence of several ferritin bands agrees with the 
findings of Richter (1964) who demonstrated at least three electro- 
phoretically distinct, but antigenically identical components in 
crystalline horse spleen ferritin, the major component comprising 
75-85$ of the total.
7. Ferritin Antiserum
An antiserum to horse spleen ferritin was prepared in rabbits 
by the method of Mazur & Shorr (1948). This antiserum has been 
shown to quantitatively precipitate rat ferritin under suitable 
conditions (in experimental data) (Mazur et al, i960). Apoferritin 
is also precipitated by the antiserum since the antibody produced 
in response to immunisation with ferritin is directed towards the 
protein moiety of ferritin (Mazur & Shorr, 1950).
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a) Preparation
Crystalline horse spleen ferritin was emulsified with complete 
FreundTs Adjuvant, which increases the antibody production, and 
injected subcutaneously into the hind legs of Californian rabbits 
on four occasions at weekly intervals. Each rabbit received a 
total of 30 mg of ferritin injected over one month, each dose being 
approximately double the previous one. The rabbits were bled 
(40 ml each) ten days after the final injection and as required.
A booster dose of ferritin was injected at approximately six monthly 
intervals to maintain the antibody titre.
The antiserum was pooled and merthiolate (l part in 10,000) 
added as preservative (Mazur & Shorr, 1950). The antisera was 
divided into small aliquots and deep frozen.
b) Immunoelectrophoresis
The specifity of the ferritin antiserum was checked by immuno- 
electrophoresis using a solution of ferritin which had not been 
passed through G.200 Sephadex to remove non-ferritin antigens.
A 1-1.5 mm thick layer of 0.8$ w/v ionagan in 0.05M barbitone 
buffer, pH 8.6, on a siliconed glass sheet, 20 x 10 cm, was allowed 
to set (30 minutes) and wells and troughs, for antigens and anti­
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bodies respectively, cut out. The agar gel was placed on the 
central compartment of the electrophoresis bath and paper wicks, 
set in the agar on long side of the glass plate, dipped into 
0.05M barbitone buffer. A few drops of ferritin solution, which 
had not been passed through G.200 Sephadex, were placed in the 
antigen well and a constant voltage, 200 V, applied for approxi­
mately four hours. (No dye marker is needed since the brown 
colour of ferritin is easily visible.) The current was switched 
off and the paper wicks removed. The trough was filled with 
ferritin antiserum, prepared as above, and the plate left in a 
damp chamber for two days after which the precipitin line was 
clearly visible. The plate was immersed in a 5$ dilution of 
40$ w/v formalin in 0.05M barbitone buffer for 30 minutes to fix 
precipitated protein. The agar gel was washed in saline for 
one day and in water for one day. The plate was stained for 
protein with an aqueous solution of kz.o black (0.2 g$ w/v) in 
ethylene glycol (25$ v/v) and was washed with water.
Results of immunoelectrophoresis
The immunoelectrophoretic pattern obtained showed only one 
precipitin line, demonstrating the presence of one ferritin 
antibody in the rabbit antiserum. (Fig. 35)
Figure 35. Immunoelectrophoretic pattern of the 
ferritin fraction before purification by G-.200 
Sephadex gel filtration, with a specific antiserum 
to crystalline horse spleen ferritin (in the trough).
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c) Standardisation of ferritin antiserum
Standardisation of ferritin antiserum was carried out using 
the "heat supernatant fraction" of liver homogenate as the source 
of ferritin antigen. 0.01 ml to 1 ml of the antiserum was added
to aliquots of liver ferritin. Ferritin was precipitated and
washed, as detailed earlier, and the iron and protein content 
determined. The precipitin curves obtained are shown in Fig. 36. 
Normally 0.5 ml antiserum was found to be sufficient to precipitate 
a.11 the ferritin in either intestinal mucosa or a small aliquot 
(2 ml) of the "heat supernatant fraction" of liver homogenate.
8. Calibration Graphs: Apoferritin and mixed protein
a) Apoferritin
The calibration curve of rat apoferritin versus optical
density was obtained from work carried out on a related project
by Drysdale (1965).
b) Mixed protein
For the determination of the protein content of heat- 
coagulated tissue, a calibration graph of mixed protein (i.e. 
a.] 1 proteins) versus optical density was required. It has
fco n
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Figure 36. Precipitin curves for ferritin protein 
and ferritin iron, in a solution obtained from 
liver homogenate, using rabbit anti-horse spleen 
ferritin serum.
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been assumed that the mixed protein concentration is given by 
the calibration curve of crystalline bovine albumin versus 
optical density, shown earlier in Fig. 30.
9- Plan of Study
Four groups of adult male rats were given respectively
(A) 0.6 mg iron as ferric ammonium citrate by gastric tube,
(B) 1.5 mg iron as ferric citrate by gastric tube, (C) 1.0 mg 
iron as iron sorbitol citric acid (Jectofer) by intramuscular 
injection, and (D) 2.5 mg iron as iron sorbitol citric acid 
by intramuscular injection. The animals were killed (by a 
sharp blow on the head) at varying intervals from 2^ to 19 
hours after iron administration; two hours before the sacrifice
14
of each rat, it was injected intraperitoneally with 5 1- C-
DL-leucine per 100 g. body weight. Control rats were given 
saline instead of the iron preparation, either by gastric 
tube or by intramuscular injection (Table 34)-
The two hour period mentioned above was chosen because 
Fineberg and Greenberg (1955 b) have shown that, in guinea 
pigs, parenteral iron stimulates the maximal incorporation of 
14C glycine into liver ferritin between 1^ and 3 hours. This
Group Total No, Weight (g) Iron per rat Times of killing
of rats Mean + S.D, Oral Parenteral after iron (hours
A 22 185 + 20 0,6 mg, ~ 2(control), 2-g-, 5
iron as 4» 5> 6.
ferric
ammonium
citrate
B 24 165 + 5  1*5 ~ 2(control), 2-g-, 5
iron as 4> 5» 6,
ferric
citrate
C 20 144 + 7 * 1 nig* iron ^(control), 5» 5»
as iron 8, 19,
sorbitol
citric
acid
54 147 +13 - 2,5 mg,iron 2(control), 5> 5>
as iron 8, 19,
£ sorbitol
citric
acid
28* 1 4 4 + 7
* In only 28 rats out of a total of 54 was the liver analysed.
TABLE 34
Details of animal experiments. Each rat was given 5 |Jic 1 * C «* 
DL - leucine /lOO g, body weight 2 hours before death. Control rats 
were given saline in place of iron.
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two hour period is a small enough fraction of the turnover time
of ferritin to ensure estimation of initial rates of incorporation.
At the same time, in such a short period, the incorporation data
14are unlikely to be seriously affd'cted by the loss of C label
due to any concurrent ferritin breakdown.
The oral preparations of iron used for Groups A & B were
14adjusted to pH 7-4 before administration. 1- C-DL-leucine was 
dissolved in sterile saline (0-9$ w/v), divided into 1 ml 
aliquots of 100 jic/ml and stored in the deep-freeze. The 
aliquots were diluted to 20 jic/ml before use.
10. Results for Group A. Oral ferric ammonium citrate 
(0.6 mg iron per rat)
A mean threefold increase over the mean of control animals 
in the synthesis of labelled ferritin in the intestinal mucosa 
occurred 4-5 hours after administration of iron, falling to 
control levels at 6 hours (Fig. 37)- Although the mean ferritin 
iron had doubled 2g hours after iron administration and remained 
high thereafter (Fig. 39), ferritin protein remained more or 
less at the control value throughout the experiment (Fig. 38).
Figure 37. Induction of 1^G labelled ferritin in 
intestinal mucosa at time intervals after 0.6 mg. 
oral iron per rat. The graph through the mean value 
is shown. Control rats, plotted at 2 hours, were 
given saline in place of iron. Each rat was given 
5 nc. 1-^C-DL-leucine intraperitoneally two 
hours before death.
Figure 38. Total ferritin protein in rat 
intestinal mucosa at time intervals after 0.6 mg. 
oral iron per rat. The graph through the mean 
values is shown. Control rats, plotted at 2 hours, 
were given saline in place of iron.
Figure 39. Total ferritin iron in rat intestinal 
mucosa at time intervals after 0.6 mg. oral iron 
per rat. The graph through the mean values is 
shown. Control rats, plotted at two hours, were 
given saline in place of iron.
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11. Results for Group B. Oral ferric citrate (1.5 mg iron 
per rat)
The mean production of radioactive ferritin in intestinal 
mucosa showed a saddle effect (Fig. 40), giving peak values at 3 
and 5 hours after iron administration (mean six and five fold rise 
respectively over the mean of control rats). At 3 hours, maximum 
ferritin iron was recorded (Table 35). Ferritin protein only 
rose above control levels at 3 and 6 hours (mean 25$ and 70$ rise 
respectively) (Fig. 42). The specific activity (c.p.m./mg 
protein) of non-ferritin protein (i.e. heated coagulated protein) 
did not show a significant variation over the 2-6 hour period 
(Fig. 41) when compared with the specific activity of ferritin,
1.e. mean 72, 189, 313 * 264, 286 and 104 c.p.m./mg protein at
2, 2g, 3, 4, 5 and 6 hours respectively.
12. Results for Group C. Intramuscular iron sorbitol 
citric acid (l mg iron per rat)
a) Intestinal Mucosa
Maximum incorporation of "^ "C leucine into intestinal mucosal 
ferritin occurred at 3 hours (mean five fold rise over the mean 
control), falling to twice the control level at 5 hours and to 
the control level at 19 hours (Fig. 43). The specific activity
Figure 40, Induction of labelled ferritin in 
intestinal mucosa at time intervals after 1.5 nig. 
oral iron per rat. The graph through the mean values 
is shown. Control rats, plotted at 2 hours, were 
given saline in place of iron. Each rat was given 
5 **c. 1-^C-DL-leucine intraperitoneally two 
hours before death.
Figure 41# Specific activity of non-ferritin
protein in intestinal mucosa at time intervals
after 1.5 mg. oral iron per rat. The graph
through the mean values is shown. Control rats,
plotted at 2 hours, were given saline in place of
14iron. Each rat was given 5 no. 1- C-DL-leucine 
intraperitoneally two hours before death.
Figure 42. Total ferritin protein in rat 
intestinal mucosa at time Intervals after 1.5 mg. 
oral iron per rat. The graph through the mean 
values is shown. Control rats, plotted at 2 
hours, were given saline in place of iron.
C.P.M. F E R R I T I N
3 0 0  -
ZOO
100 ■
400 1 n o n-ferritin protein
C.RM./-mg PROTEIN
ZOO -
1.0
mg FERRITIN PROTEIN
Hours after iron adminis tration
2* 2i 3 4 5 6
Ferritin 22.3 15.1 27.4 18.0 19.6 20.1
Iron 10.7 9.9 13.9 17.8 13.8 24.7
(neO 16.0 15.2 23.4 12.3 11.2 13.0
4.1 22.0 20.7 19.6 12.5 13.5
MEAN 15.3 15.5 21.3 17.0 14.3 17.8
* Control rats. These were given saline in place of i:
TABLE 35
Total ferritin iron in rat intestinal mucosa at 2-g-, 3> 
4, 5 and 6 hours after the administration of 1*5 nig. 
oral iron.
Figure 43. Induction of ^ C  labelled ferritin in 
intestinal mucosa at time intervals after 1 mg. 
parenteral iron per rat. The graph through the 
mean values is shown. Control rats, plotted at 2 
hours, were given saline in place of iron. Each 
rat was given 5 i^ c. 1-^C-DL-leucine 
intraperitoneally two hours before death.
Figure 44. Specific activity of ferritin in
intestinal mucosa at time intervals after 1 mg.
parenteral iron per rat. The graph through the
mean values is shown. Control rats, plotted at 2
hours, were given saline in place of iron. Each
14rat was given 5 nc. 1- C-DL-leucine 
intraperitoneally two hours before death.
Figure 45. Specific activity of non-ferritin 
protein in intestinal mucosa at time intervals 
after 1 mg. parenteral iron per rat. The graph 
through the mean values is shown. Control rats, 
plotted at 2 hours, were given saline in place of 
iron. Each rat was given 5 no. 1-"^ C-DL-leucine 
intraperitoneally two hours before death.
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of ferritin (Fig. 44) is similar to that of the activity of 
ferritin (Fig. 43) but quite different to the specific activity 
of non-ferritin protein (Fig. 45), showing that iron stimulates 
the synthesis of ferritin protein but not the synthesis of other 
proteins.
At 3 hours, the mean ferritin iron was double the mean 
of control rats, and remained high until 8 hours. At 19 hours, 
it approached control level (Fig. 46). Ferritin protein 
levels remained more or less constant throughout the experiment 
(Fig. 47).
b) Liver
14In liver, a mean seven fold increased synthesis of C 
labelled ferritin occurred 5 hours after iron injection. The 
activity of ferritin remained high at 8 hours, returning to the 
control level at 19 hours (Fig. 48)- As in intestinal mucosa, 
the specific activity of liver ferritin (Fig. 49) was similar 
to that of the activity of ferritin (Fig. 1+8) but was quite 
different to the specific activity of mixied liver protein 
(Fig. 50). There was a significant increase in liver ferritin 
protein, maximal 8 hours after injection of iron, representing
Figures 46 and 47. Total ferritin iron and 
ferritin protein respectively in intestinal mucosa 
at time intervals after 1 mg. parenteral iron per 
rat. The- graph through the mean values is shown. 
Control rats, plotted at 2 hours, were given saline 
in place of iron.
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Figure 48. Induction of 1^G labelled ferritin in 
liver at time intervals after 1 mg. parenteral 
iron per rat. The graph through the mean values 
is shown. Control rats, plotted at 2 hours, were 
given saline in place of iron. Each rat was given 
5 nc. 1-^C-DL-leucine intraperitoneally two 
hours before death.
Figure 49. Specific activity of liver ferritin 
at time intervals after 1 mg. parenteral iron per 
rat. The graph through the mean values is shown. 
Control rats, plotted at 2 hours, were given 
saline in place of iron. Each rat was given 5 nc. 
1-^C-DL-leucine intraperitoneally two hours 
before death.
Figure 50. Specific activity of non-ferritin
protein in liver at time intervals after 1 mg.
parenteral iron per rat. The graph through the
mean values is shown. Control rats, plotted at
2 hours, were given saline in place of iron.
1 4Each rat was given 5 nc. 1- C-DL-leucme 
intraperitoneally two hours before death.
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a mean two fold rise over the mean control (Table 36). Ferritin 
iron showed a mean two fold rise over the mean control at 3 hours. 
Although it had fallen slightly at 5 hours, this level was main­
tained until 19 hours (Table 36).
13. Results for Group D. Intramuscular iron sorbitol citric
acid (2.5 mg iron per rat)
a) Intestinal Mucosa
14The synthesis of C labelled ferritin in intestinal mucosa, 
high at 3 hours, reached a maximum at 5 hours after iron injection, 
showing a mean tenfold rise over the mean of control rats. * At 
19 hours, the activity of ferritin approached that of the control 
rats (Fig. 5l)» Ferritin iron, high at 3 hours, reached a 
plateau 5 hours after iron injection. At 19 hours, the value 
remained unchanged, giving a mean fourfold rise over the mean 
of control rats (Fig. 52). Ferritin protein rose by 60$ at 
three hours and reached a maximum (2g times the mean control 
value) at 5-8 hours. 19 hours after iron injection, ferritin 
protein was still double the control value (Fig. 53)-
Hours after iron injection
2* 3 5 8 19
Liver 128 169 182 174 33
Ferritin 46 171 127 304 341
Iron 143 341 182 191 133
0*g.) 201 416 414 253 400
MEAN 130 274 226 231 252
Liver 3*07 5*37 4.38 5.78 3.54
Ferritin 3*94 5.43 6.14 5.14 5.47
Protein 3*91 4*95 5.32 5.58 1.45
(mg*) 2,27 5.18 3*96 7.57 7.53
MEAN 3.30 5.23 4.95 6..02 4.65
* Control rats. These were given saline in place of iron
TABLE 56
Total ferritin iron and ferritin protein in rat liver 
at 3, 5, 8 and 19 hours after the administration of 1 mg# 
of parenteral iron*
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b) Liver
In the livers of these rats, there was an enhanced synthesis
14of C labelled ferritin which was maximal 8 hours after iron 
injection (mean twentyfold rise over the mean control value) and 
fell to near control levels at 19 hours (Fig. 5l)« Liver 
ferritin protein was still rising 19 hours after iron injection. 
The mean value at 19 hours was thrice that of the mean of control 
rats (Fig. 53)- Liver ferritin iron (Fig. 52) followed a 
similar pattern to liver ferritin protein (Fig. 53)> rising 
more swiftly initially but still increasing at 19 hours after 
iron injection when the mean value was three times that of mean 
value for control animals.
In both intestinal mucosa and liver, the specific, activity 
of non-ferritin protein was similar to that in Group C, showing 
no significant variation. The fact that the specific activity 
of the non-ferritin protein remains constant emphasises the 
specificity of action of iron on ferritin synthesis, rather 
than on protein synthesis in general.
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Section D.III 
Discussion
These experiments have demonstrated that the intramuscular
injection of 1 or 2-5 mg of iron as iron sorbitol citric acid
provokes a 5 - 10 fold increase of ferritin synthesis in the
intestinal mucosa of the rat, as shown by the incorporation of 
14
C labelled leucine into ferritin. The rise in ferritin 
synthesis was maximal about 3 to 5 hours after the injection 
of iron and gradually declined after about 8 hours. At the 
same time, with 2.5 mg of iron sorbitol citric acid, there was 
an increasing content of mucosal ferritin protein and ferritin 
iron; these increments were maximal at about 5 to 8 hours and 
remained high until 19 hours after injection. There was a 
3 and 6 fold stimulation of ferritin synthesis in the rat 
intestinal mucosa when oral iron was given in a dose of 0.6 mg 
and 1.5 mg respectively to each rat. There has also been 
confirmation of the findings of other authors (Fineberg and 
Greenberg, 1955 a, and Drysdale and Munro, 1966) of the effect 
of parenteral iron on hepatic ferritin synthesis. The 
increased rate of ferritin synthesis in the liver was however
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twice that which occurred in the intestinal mucosa, that is 
a 20-fold rise as against a 10-fold rise in the intestinal 
mucosa after 2-5 mg of iron in iron sorbitol. It can be 
argued that these doses of iron are grossly in excess of a 
comparable dose given weight for weight to man or a comparable 
amount of iron which might reach the intestinal mucosa.
On the other hand over 30% of the iron in iron sorbitol is 
excreted in the kidney (Pringle et al, 1962) and only a 
proportion of the iron will in fact reach the intestinal 
mucosa after the parenteral route. Although the level of 
iron is greatly in excess of that which is achieved by an 
ordinary meal containing iron, it is not unusual for a 
dose of 200 - 400 mg of iron to be presented to the human 
intestinal mucosa in treatment of iron deficiency anaemia, 
a dose which is comparable with that given to the rats in 
the present experiments.
How can these results be interpreted in the light of 
CrosbyTs concept of iron absorption and excretion by the 
intestinal mucosal cells? From the present studies it would 
seem reasonable to suggest that the presence of ferritin in
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the mucosal cell is influenced by the amount of iron which 
passes into it and that in states of iron deficiency, where 
there is little iron in any of the cells of the body, there 
is consequently very little ferritin or apoferritin in these 
mucosal cells. This absence of the nferritin curtain” allows 
the unobstructed passage of iron through the cell. On the 
other hand in iron loaded states a considerable amount of iron 
present within the cell will provoke the synthesis of apoferritin 
to trap incoming iron, which is then excreted as ferritin when 
the cell is sloughed off. This will therefore diminish iron 
absorption in the iron loaded state (Fig. 54)- These results 
substantiate Crosbyfs hypothesis and answer a question which 
this hypothesis has presented, namely why there is little 
mucosal ferritin in iron deficiency, but ample in states of 
iron repletion. They also help to explain how iron absorption 
and excretion may be controlled by the iron content of the 
body.
Although the exact mechanism of increased ferritin 
synthesis by iron in the intestinal mucosa has not been studied 
in the present experiments, such a mechanism may be surmised
Fe lost with sloughed cell 
Unaccepted Fe
Fe in gut lumen  
Fe Accepted byce
Absorbed Fe
N O R M A L
RON DEFICIENT
spy.,.'--
RON LOADED
Figure 54. Control of iron absorption by the 
intestinal mucosa. In iron overload, there is much 
ferritin present in the mucosal cell and this tends 
to trap incoming iron, thus preventing absorption. 
In iron deficiency, there is little or no ferritin 
present, allowing iron to pass freely through the 
cell to be absorbed into the bloodstream.
153
from the work of Drysdale and Munro, 1966, on the mechanism 
of increased ferritin synthesis in rat liver after parenteral- 
iron injection- The latter authors showed that the increased 
ferritin synthesis did not depend upon an increased production 
of messenger RNA since the stimulation was unaffected by 
actinomycin D, which blocks the synthesis of messenger - RNA. 
They concluded that iron causes an apparent induction of 
ferritin by stabilising apoferritin. Studies are in progress 
to challenge the possibility that this mechanism also occurs 
in the intestinal mucosa of the rat.
Summary
It has been suggested that the iron incorporated into 
ferritin of intestinal mucosa provides a means for the 
excretion of unrequired iron. In iron deficiency there is 
little mucosal ferritin but in states of iron repletion 
there is ample.
In the present study oral and parenteral adminis­
tration of iron in the rat caused a 3 to 10 fold increase 
respectively in ferritin synthesis in intestinal mucosa,
assayed by the rate of incorporation of l-^C-DL-leucine 
into ferritin. Small scale isolation of mucosal ferritin 
was achieved by using a specific antiserum prepared by 
injection of horse spleen ferritin into rabbits.
These results help to explain how iron absorption and 
excretion may be controlled by the iron content of the body.
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